Formulations for non-parenteral administration of exosomes
Patent Information
- Application Number
- JP2023535362
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-11
- Filing Date
- 2021-12-10
- Publication Date
- 2024-12-09
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods for delivering exosomes non-parenterally, such as orally or rectally, face challenges in maintaining exosome integrity and efficacy due to the harsh conditions of the gastrointestinal tract, particularly the acidic environment of the stomach.
Formulations comprising mammalian exosomes mixed with a matrix of methylcellulose and alginate gel, surrounded by an enteric coating, designed to release exosomes at specific pH levels within the gastrointestinal tract, ensuring their protection and targeted delivery to the ileum, colon, or rectum/vagina.
The formulations effectively protect exosomes from degradation and ensure their targeted release, maintaining a high recovery rate and therapeutic efficacy, with up to 60% or more exosomes remaining intact after 2 hours at pH 1.2, and providing therapeutic benefits for inflammatory disorders.
Smart Images

Figure 00000000_0001_ABST 
Figure 00000000_0000_ABST
Abstract
Description
Technical Field
[0001] Cross-reference This application claims the benefit of U.S. Provisional Patent Application No. 63 / 124,312, filed on December 11, 2020, the entire disclosure of which is incorporated herein by reference.
[0002] This specification describes formulations and compositions useful for non-parenteral administration of exosomes.
Summary of the Invention
Means for Solving the Problems
[0003] In one embodiment, a composition for oral delivery of mammalian exosomes is described herein, comprising a plurality of mammalian exosomes mixed with a matrix and surrounded by an enteric coating, the matrix comprising about 0.1% to about 5.0% methylcellulose and about 0.1% to about 5.0% alginate gel. In a particular embodiment, the matrix comprises about 0.5% to about 1.0% methylcellulose and about 0.5% to about 1.0% alginate gel. In a particular embodiment, the matrix comprises about 0.25% to about 0.75% methylcellulose and about 0.25% to about 0.75% alginate gel. In a particular embodiment, the matrix comprises about 0.5% to about 3.0% methylcellulose and about 0.5% to about 3.0% alginate gel. In certain embodiments, the matrix comprises about 1.0% to about 2.0% methylcellulose and about 1.0% to about 2.0% alginate gel. In certain embodiments, the matrix comprises about 1.3% to about 1.8% methylcellulose and about 1.3% to about 1.8% alginate gel. In certain embodiments, the matrix comprises about 1.5% methylcellulose and about 1.5% alginate gel. In certain embodiments, the matrix comprises a methylcellulose to alginate gel ratio of about 1:1. In certain embodiments, the exosomes are mesenchymal stem cell exosomes or hematopoietic stem cell exosomes. In certain embodiments, the exosomes are hematopoietic stem cell exosomes. In certain embodiments, the exosomes are mesenchymal stem cell exosomes. In certain embodiments, the mesenchymal stem cells are type I mesenchymal stem cells. In certain embodiments, the mesenchymal stem cells are type II mesenchymal stem cells. In certain embodiments, the exosomes contain proteins or nucleic acids selected from the list consisting of CD81, CD63, CD9, HSP60, HSP70, HSP90, VEGF, PGE2, and combinations thereof. In certain embodiments, the exosomes contain nucleic acids selected from the list consisting of miRNA Let7, 155, 146, 122, and combinations thereof.In certain embodiments, mammalian exosomes have a diameter of about 30 nanometers to about 150 nanometers. In certain embodiments, mammalian exosomes are human exosomes. In certain embodiments, mammalian exosomes are exosomes of dogs, cats, cattle, horses, sheep, or pigs. In certain embodiments, the enteric coating comprises a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the enteric coating essentially consists of a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the composition contains at least 100 billion exosomes. In certain embodiments, the composition contains at least 100 billion to 2 trillion exosomes.
[0004] In further embodiments, compositions for non-parenteral and / or transrectal or transvaginal delivery of mammalian exosomes are described herein, comprising a lipophilic or hydrophilic coating surrounding a plurality of mammalian exosomes mixed with a solid matrix, the matrix comprising about 0.5% to about 3.0% methylcellulose and about 0.5% to about 3.0% alginate gel. In certain embodiments, the matrix comprises about 1.0% to about 2.0% methylcellulose and about 1.0% to about 2.0% alginate gel. In certain embodiments, the matrix comprises about 1.3% to about 1.8% methylcellulose and about 1.3% to about 1.8% alginate gel. In certain embodiments, the matrix comprises about 1.5% methylcellulose and about 1.5% alginate gel. In certain embodiments, the matrix comprises a methylcellulose to alginate gel ratio of about 1:1. In certain embodiments, the exosome is a mesenchymal stem cell exosome or a hematopoietic stem cell exosome. In certain embodiments, the exosome is a hematopoietic stem cell exosome. In certain embodiments, the exosome is a mesenchymal stem cell exosome. In certain embodiments, the mesenchymal stem cell is a type I mesenchymal stem cell. In certain embodiments, the mesenchymal stem cell is a type II mesenchymal stem cell. In certain embodiments, the exosome contains a protein or nucleic acid selected from the list consisting of CD81, CD63, CD9, HSP60, HSP70, HSP90, VEGF, PGE2, and combinations thereof. In certain embodiments, the exosome contains a nucleic acid selected from the list consisting of miRNA Let7, 155, 146, 122, and combinations thereof. In certain embodiments, the mammalian exosome has a diameter of about 30 nanometers to about 150 nanometers. In certain embodiments, the mammalian exosome is a human exosome. In certain embodiments, the mammalian exosomes are exosomes from dogs, cats, cattle, horses, sheep, or pigs. In certain embodiments, the composition is formulated for transrectal delivery. In certain embodiments, the composition is formulated for transvaginal delivery. In certain embodiments, the formulation does not swell upon contact with an aqueous medium.In certain embodiments, the lipophilic or hydrophilic coating melts at normal body temperature or above 36°C. In certain embodiments, the lipophilic or hydrophilic coating essentially consists of cocoa butter, coconut oil, glycerin gelatin, hydrogenated oil, polyethylene glycol (PEG), fatty acid esters of PEG, or a lipophilic base from Gattefosse. In certain embodiments, the lipophilic or hydrophilic coating contains cocoa butter, coconut oil, glycerin gelatin, hydrogenated oil, polyethylene glycol (PEG), fatty acid esters of PEG, or a lipophilic base from Gattefosse. In certain embodiments, the enteric coating essentially consists of a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the composition contains at least 100 billion exosomes. In certain embodiments, the composition contains at least 100 billion to 2 trillion exosomes. In certain embodiments, after incubation at pH 1.2 for 2 hours, more than 40% of intact exosomes are recovered from the composition compared to the initial amount. In certain embodiments, after incubation at pH 1.2 for 2 hours, more than 50% of intact exosomes are recovered from the composition compared to the initial amount. In certain embodiments, after incubation at pH 1.2 for 2 hours, more than 60% of intact exosomes are recovered from the composition compared to the initial amount.
[0005] In one embodiment, the compositions described herein may be used in a method for treating an inflammatory disorder or autoimmune disorder in an individual, comprising administering the composition non-parentally, orally, vaginally, or rectally to the individual. In certain embodiments, the individual is a human individual. In certain embodiments, the individual is a dog, cattle, cattle, pig, horse, or sheep. In certain embodiments, the inflammatory disorder or autoimmune disorder is an inflammatory disorder or autoimmune disorder of the gastrointestinal tract. In certain embodiments, the inflammatory disorder or autoimmune disorder of the gastrointestinal tract includes inflammatory bowel disease or Crohn's disease. In certain embodiments, the inflammatory disorder or autoimmune disorder of the gastrointestinal tract includes Crohn's disease. Furthermore, a method for reducing neutrophil accumulation or neutrophil activation in the gastrointestinal tract of an individual is also described herein, which comprises administering the composition described herein to the individual.
[0006] Novel features described herein are described in detail in the appended claims. The features described herein and their advantages will be better understood by referring to the following detailed description and the appended drawings, which describe exemplary embodiments utilizing the principles of each feature described herein. [Brief explanation of the drawing]
[0007] [Figure 1] A typical diagram of an oral exosome delivery capsule is shown. In the upper diagram of single-capsule monophase delivery, therapeutic mammalian exosomes may be appropriately sourced and manufactured, added or mixed into a matrix, packaged in a capsule, and finally coated with an enteric coating. In another embodiment, therapeutic mammalian exosomes may be manufactured and added or mixed into a matrix, similar to how they were before being packaged in a single capsule. Subsequently, a second dose of exosomes may be mixed into the matrix and packaged in a capsule, which may then be placed inside the first capsule, as shown in the lower diagram of capsule-in-capsule biphase delivery. [Figure 2]A representative and non-limiting diagram of the oral delivery of exosome-containing capsules and their intended deployment in the ileum and colon is shown. In single-capsule monophase delivery (left) or capsule-in-capsule biphase delivery (right), therapeutic mammalian exosomes are ingested orally and pass through the mouth, esophagus, and duodenum. As illustrated, the enteric-coated protective coating disappears and the exosomes are deployed in the targeted ileum (pH 7.3–8) and subsequently in the colon (pH 5.5–6.5). [Figure 3] Typical diagrams of transrectal or transvaginal exosome delivery capsules are shown. In the upper diagram of single-capsule monophase delivery, therapeutic mammalian exosomes may be manufactured, added or mixed into a matrix, packaged in a capsule, and finally coated with an enteric coating. In another embodiment, therapeutic mammalian exosomes may be appropriately sourced, manufactured, and added or mixed into a matrix, as before being packaged in a single capsule. Subsequently, a second dose of exosomes may be mixed into the matrix and packaged in a capsule, which may then be placed inside the first capsule, as shown in the lower diagram of capsule-in-capsule biphase delivery. [Figure 4] A representative and non-limiting diagram is shown of the transrectal or transvaginal delivery of exosome-containing capsules and their intended deployment in the ileum and colon. In single-capsule monophase delivery (left) or capsule-in-capsule biphase delivery (right), therapeutic mammalian exosomes are ingested orally and pass through the mouth, esophagus, and duodenum. As illustrated, the hydrophilic or lipophilic protective coating disappears and the exosomes are deployed in the targeted vagina (pH 3.8–4.7) or rectum (pH 5.5–8.0) and subsequent colon (pH 5.5–6.5). [Figure 5] This specification shows the manufacturing scheme for the delivery system described herein. [Figure 6]This shows that exosome particles are released from the oral formulation capsule after reaching a neutral pH. The exosomes were derived from adult human mesenchymal stem cells and added to an oral formulation with an enteric coating, then incubated at the indicated pH. Figure 6A shows a heatmap of the data. Figure 6B shows the number of CD63, CD9, or CD81 expressing exosomes recovered from incubation at each pH. Figure 6C shows an immunofluorescence microscopy image showing that intact exosomes were recovered. [Figure 7] This shows that exosome particles are released from the oral formulation capsule only after incubation in simulated gastric juice or simulated intestinal fluid. Figure 7A shows a heatmap of the data. Figure 7B shows the number of CD63, CD9, or CD81 expressing exosomes recovered from simulated gastric juice (SIG) or simulated intestinal fluid (SIF). Figure 7C shows an immunofluorescence microscopy image showing that intact exosomes were recovered. [Figure 8] This study demonstrates that oral exosome therapy alleviates IBD colitis in a mouse model. Figure 8A shows the experimental conditions. Figure 8B shows the scoring for the in vivo model. [Figure 9] This demonstrates that the recovered exosomes retain anti-inflammatory capabilities. [Modes for carrying out the invention]
[0008] This specification describes a composition for the non-parenteral delivery of mammalian exosomes, comprising a plurality of mammalian exosomes mixed with a matrix, the matrix comprising an alginate gel. In certain embodiments, the composition is for oral delivery. In certain embodiments, the composition releases mammalian exosomes at a pH of about 6.4, 6.6, 6.8, or 7.0 or higher.
[0009] This specification describes a composition for the non-parenteral delivery of mammalian exosomes, comprising a plurality of mammalian exosomes mixed with a matrix, the matrix comprising methylcellulose. In certain embodiments, the composition is for oral delivery. In certain embodiments, the composition releases mammalian exosomes at a pH of about 6.4, 6.6, 6.8, or 7.0 or higher.
[0010] This specification describes a composition for the non-parenteral delivery of mammalian exosomes, comprising a plurality of mammalian exosomes mixed with a matrix and surrounded by an enteric coating, the matrix comprising an alginate gel. In certain embodiments, the composition is for oral delivery. In certain embodiments, the composition releases mammalian exosomes at a pH of about 6.4, 6.6, 6.8, or 7.0 or higher.
[0011] This specification describes a composition for the non-parenteral delivery of mammalian exosomes, comprising a plurality of mammalian exosomes mixed with a matrix and surrounded by an enteric coating, the matrix comprising methylcellulose. In certain embodiments, the composition is for oral delivery. In certain embodiments, the composition releases mammalian exosomes at a pH of about 6.4, 6.6, 6.8, or 7.0 or higher.
[0012] This specification describes a composition for the non-parenteral delivery of mammalian exosomes, comprising a plurality of mammalian exosomes mixed with a matrix and surrounded by an enteric coating, the matrix comprising a methylcellulose and alginate gel. In certain embodiments, the composition is for oral delivery. In certain embodiments, the composition releases mammalian exosomes at a pH of about 6.4, 6.6, 6.8, or 7.0 or higher.
[0013] This specification describes a composition for oral delivery of mammalian exosomes, comprising a plurality of mammalian exosomes mixed with a matrix and surrounded by an enteric coating, the matrix comprising about 0.1% to about 5.0% methylcellulose and about 0.1% to about 5.0% alginate gel.
[0014] The following description includes specific details to provide a complete understanding of the various embodiments. However, those skilled in the art will understand that the embodiments provided may be carried out without these details. Throughout the following specification and claims, unless the context requires otherwise, the word “comprise” and its variations such as “comprises” and “comprising” should be interpreted in an open and comprehensive sense, i.e., “including, but not limited to.” As used herein and in the appended claims, the singular forms “a,” “an,” and “the” refer to multiple subjects unless explicitly stated otherwise. Also note that the term “or” is generally used to mean “and / or” unless explicitly stated otherwise. Furthermore, the headings provided herein are for convenience only and are not intended to interpret the scope or meaning of the claimed embodiments.
[0015] The compositions described herein may "essentially consist of" the specified components, which may include other active ingredients, as well as other diluents, carriers, and excipients (often included to contribute to administerability or stability) that do not alter the fundamental properties of the composition, although they exclude the specified components.
[0016] As used herein, "non-parenteral" refers to any enteral route of administration, including via the mouth, rectum, or nasal route. Furthermore, as used herein, "non-parenteral" also refers to vaginal administration.
[0017] As used herein, the term "about" refers to an amount close to within 10% of the recited amount.
[0018] As used herein, the terms "individual," "patient," or "subject" refer to an individual who has been diagnosed with at least one disease, is suspected of having the disease, or is at risk of developing the disease, and for whom the described compositions and methods are useful for treating the disease. In certain embodiments, the individual is a mammal. In certain embodiments, the mammal is a mouse, rat, rabbit, dog, cat, horse, cow, sheep, pig, goat, llama, alpaca, or yak. In certain embodiments, the individual is a human.
[0019] The terms "polypeptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues, with no limitation as to minimum length. Polypeptides that include the provided antibodies and antibody chains, as well as other peptides such as, for example, linkers and binding peptides, may include amino acid residues that contain natural and / or non-natural amino acids. The term also includes post-expression modifications of polypeptides, such as, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like. In some embodiments, a polypeptide may include modifications to the native or natural sequence as long as the protein maintains the desired activity. These modifications may be intentional, such as by site-directed mutagenesis, or may be accidental, such as mutations in the host producing the protein or errors due to PCR amplification.
[0020] As used herein, the term "hematopoietic stem cell" and grammatical equivalents refer to stem cells that give rise to other blood cells, including red blood cells; platelets; lymphoid cells such as T cells and B cells; and myeloid cells such as monocytes, macrophages, eosinophils, basophils, mast cells, and neutrophils. Hematopoietic stem cells according to the present disclosure are cells that can give rise to at least lymphoid and myeloid cells. A common surface marker of hematopoietic stem cells includes CD34. Hematopoietic stem cells may also include surface markers such as EPCR and CD90. Hematopoietic stem cells can be identified by any one or more of CD34, EPCR, and CD90. Such surface positivity can be determined, for example, by immunohistochemistry or flow cytometry. Hematopoietic stem cells can be suitably isolated from bone marrow, cord blood, and peripheral blood. Hematopoietic stem cells can be cultured using methods known in the art. See, for example, Frisch et al., "Hematopoietic Stem Cell Cultures and Assays.", Methods Mol Biol. 2014;1130:315-324.
[0021] As used herein, the term "mesenchymal stem cell" and grammatical equivalents refer to stem cells of mesenchymal origin. This term refers to cells that can differentiate into at least two or more of osteoblasts, chondrocytes, adipocytes, or myocytes. MSC may be isolated from any type of adult tissue. Usually, MSC is isolated from bone marrow, adipose tissue, umbilical cord, or peripheral blood. As described in Waterman et al., "A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype.", PLoS One. 2010;5(4):e10088, MSC can be divided into pro-inflammatory MSC type I and anti-inflammatory MSC type II. Methods for inducing various MSC types are described, for example, in U.S. Patent Application Publication No. 20140017787(A1) and U.S. Patent Application Publication No. 20160097038(A1).
[0022] As used herein, “exosome” (abbreviated as EV), and its grammatical equivalent, refers to a membrane-bound extracellular vesicle produced by many eukaryotic cells. These vesicles may contain proteins and nucleic acids such as DNA, RNA, mRNA, and miRNA. Exosomes can be generated from cultured cells by a wide variety of methods. Such methods include, for example, centrifugation techniques and commercially available kits. See Lane et al., “Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing,” Scientific Reports volume 5, Article number: 7639 (2015); Li et al., “Progress in exosome isolation techniques,” Theranostics. 2017; 7(3): 789-804, International Publication No. 2019035880(A1), and International Publication No. 2019231562(A1).
[0023] In certain embodiments, the EV according to the Disclosure has a diameter of about 25 nm to about 150 nm. In certain embodiments, the EV according to the Disclosure has a diameter of about 25 nm to about 50 nm, about 25 nm to about 75 nm, about 25 nm to about 100 nm, about 25 nm to about 125 nm, about 25 nm to about 150 nm, about 50 nm to about 75 nm, about 50 nm to about 100 nm, about 50 nm to about 125 nm, about 50 nm to about 150 nm, about 75 nm to about 100 nm, about 75 nm to about 125 nm, about 75 nm to about 150 nm, about 100 nm to about 125 nm, about 100 nm to about 150 nm, or about 125 nm to about 150 nm. In certain embodiments, the EV according to the Disclosure has a diameter of about 25 nm, about 50 nm, about 75 nm, about 100 nm, about 125 nm, or about 150 nm. In certain embodiments, the EV according to the Disclosure has a diameter of at least about 25 nm, about 50 nm, about 75 nm, about 100 nm, or about 125 nm. In certain embodiments, the EV according to the Disclosure has a diameter of up to about 50 nm, about 75 nm, about 100 nm, about 125 nm, or about 150 nm.
[0024] Exosome recovery from compositions described herein refers to the recovery rate after a predetermined event, such as incubation, compared to the number of exosomes initially present in the composition. Established techniques for determining the (average) size and concentration of exosomes include electron microscopy (EM), dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), resistance pulse sensing, and fluorescence correlation spectroscopy. For the purposes of this disclosure, the number or size of particles is measured by either standard flow cytometry or high-resolution flow cytometry, depending on the size of the exosomes. For example, see van der Vlist EJ, Nolte-'T Hoen EN, Stoorvogel W, et al. "Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry." Nat Protoc. 2012 / 06 / 23.2012;7(7):1311-1326.
[0025] Oral delivery system As shown in Figure 1, one embodiment of the delivery system described is a monophase delivery system. The monophase delivery system comprises a plurality of exosomes and a pH-sensitive enteric coating. As shown in Figure 1, another embodiment of the delivery system described is a biphase delivery system. The biphase delivery system comprises a first plurality of exosomes encapsulated within an enteric coating and a second plurality of exosomes within the enteric coating. The first plurality of exosomes surround the second plurality of exosomes, so that the first plurality of exosomes are released at a first pH and the second plurality of exosomes are left for release at a second pH. As a result, the biphase delivery system can deliver two different plurality of exosomes to two different locations in the digestive tract of an individual, as shown in Figure 2. In certain embodiments, the first and second plurality of exosomes contain the same type of cell. In certain embodiments, the first and second plurality of exosomes contain different types of exosomes. In certain embodiments, the exosomes are embedded in a matrix and then surrounded by an enteric coating. The matrix protects the exosomes from osmotic stress, pH stress, and mechanical disruption until they are released at the intended delivery site, which may include one or more of the ileum, jejunum, duodenum, or colon. Such a system helps deliver therapeutic exosomes to an individual via non-parental and oral routes. Figure 3 provides an overview of the process for preparing and distributing the oral exosome composition described herein.
[0026] Rectal or vaginal delivery system As shown in Figure 3, one embodiment of the delivery system described is a single-phase delivery system. The single-phase delivery system comprises an exosome preparation and a pH-sensitive lipophilic or hydrophilic coating. As shown in Figure 3, another embodiment of the delivery system described is a two-phase delivery system. The two-phase delivery system comprises a first exosome preparation encapsulated within a lipophilic or hydrophilic coating and a second exosome preparation within the lipophilic or hydrophilic coating. The first exosome preparation surrounds the second exosome preparation, so that the first exosome preparation is released at a first pH and the second exosome preparation is left for release at a second pH. As a result, the two-phase delivery system can deliver two different exosome preparations to two different locations in the digestive tract of an individual, as shown in Figure 4. In certain embodiments, the first and second exosome preparations contain the same type of exosome. In certain embodiments, the first and second exosome preparations contain different types of exosomes. In certain embodiments, exosomes are embedded in a matrix and then surrounded by a lipophilic or hydrophilic coating. The matrix protects the exosomes from osmotic stress, pH stress, and mechanical damage until they are released at the intended delivery site, which may include one or more of the colon, large intestine, small intestine, appendix, cecum, colon, rectum, duodenum, jejunum, ileum, or vagina. Such a system helps deliver therapeutic exosomes to an individual via the rectal or vaginal pathway. Figure 3 provides an overview of the process for preparing and distributing the transrectal or transvaginal exosome preparation compositions described herein.
[0027] Furthermore, the formulation may include a pharmaceutically acceptable organic or inorganic carrier substance that does not react adversely with the components of the composition and is suitable for non-parenteral administration. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohol, polyethylene glycol, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone, or any combination thereof. The formulation can be sterilized and, if desired, can be mixed with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts that affect osmotic pressure, buffers, colorants, flavorings, aromatics, or any combination thereof.
[0028] The compositions of the present invention may be formulated as suspensions in aqueous, non-aqueous, or mixed media. The aqueous suspension may further contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, and / or dextran. The suspension may also contain stabilizers.
[0029] The compositions of the present invention may be prepared and formulated as emulsions or containing emulsions. The emulsions may contain further components, which may exist as solutions in either the aqueous or oil phase, or as separate phases themselves. Optionally, the emulsions may also contain pharmaceutically acceptable excipients such as emulsifiers, stabilizers, dyes, and antioxidants. Pharmaceutical emulsions may also be multiple emulsions comprising more than two phases, such as oil-in-water emulsions and water-in-oil emulsions. Emulsions according to the present invention include oil-in-water emulsions, water-in-oil emulsions, oil-in-water emulsions, and water-in-oil emulsions. Emulsions may have little to no thermodynamic stability. Often, the dispersed or discontinuous phases of the emulsion are well dispersed in the outer or continuous phase and maintained in this form by the viscosity of the emulsifier or formulation. Any of the phases of the emulsion may be semi-solid or solid. Another means of stabilizing the emulsion is, of course, the use of emulsifiers, which may be incorporated into any of the phases of the emulsion.
[0030] Natural emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin, and acacia. Absorption bases such as dehydrated lanolin and hydrophilic petrolatum have hydrophilic properties that allow them to absorb water to form water-in-oil emulsions while maintaining the viscosity of their semi-solid state. Fine powders are also used as excellent emulsifiers, especially in combination with surfactants or in viscous preparations. These include polar inorganic solids such as heavy metal hydroxides, non-swelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate, and colloidal magnesium aluminum silicate, pigments, and non-polar solids such as carbon or glyceryl tristearate.
[0031] Various non-emulsifying substances are also included in emulsion formulations and contribute to the properties of the emulsion. These include fats, oils, waxes, fatty acids, aliphatic alcohols, fatty acid esters, wetting agents, hydrophilic colloids, preservatives, antioxidants, or any combination thereof. Examples of hydrophilic colloids include natural rubber and synthetic polymers, such as polysaccharides (e.g., acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (e.g., carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (e.g., carbomer, cellulose ether, carboxyvinyl polymer).
[0032] Commonly used preservatives in emulsion formulations include methylparaben, propylparaben, quaternary ammonium salts, benzalkonium chloride, p-hydroxybenzoic acid esters, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration. The antioxidants used may be free radical scavengers such as tocopherol, alkyl gallate, butylhydroxyanisole, and butylhydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, as well as antioxidant synergistic agents such as citric acid, tartaric acid, and lecithin.
[0033] The compositions of the present invention may be prepared and formulated as microemulsions or containing microemulsions. Microemulsions may improve drug solubilization, protect drugs from enzymatic hydrolysis, potentially enhance drug absorption through changes in membrane fluidity and permeability by surfactants, potentially improve ease of preparation and oral administration compared to solid dosage forms, enhance clinical efficacy, and reduce toxicity. In many cases, microemulsions can form spontaneously at ambient temperature. The microemulsion compositions and formulations of the present invention may not only promote systemic absorption of the composition from the gastrointestinal tract but may also improve local cellular uptake of delivered exosome preparations in the gastrointestinal tract, vagina, and other areas of non-parenteral administration.
[0034] Furthermore, the microemulsion of the present invention may further contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsion of the present invention can be classified as belonging to one of five broad categories: surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants.
[0035] The compositions of the present invention can be processed by known methods into common formulations such as capsules, coated capsules, tablets, coated tablets, pills, pellets, granules, aerosols, syrups, emulsions, suspensions, gels, lotions, pastes, creams, balms, and solutions, or any combination thereof, using inert, non-toxic, pharmaceutically acceptable excipients or solvents. In each case, the therapeutically active compound should be present in an amount calculated to ensure the desired therapeutic effect. The compositions may be formulated by conventional methods using additional pharmaceutically acceptable carriers or excipients as needed. Thus, the compositions may be prepared by conventional means using carriers or excipients such as binders (e.g., pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose), fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate), lubricants (e.g., magnesium stearate, talc, or silica), disintegrants (e.g., starch or sodium starch glycolate), or wetting agents (e.g., sodium lauryl sulfate).
[0036] In some embodiments, the composition of the present invention may further contain hydroxypropyl methylcellulose (HPMC).
[0037] In some embodiments, the composition of the present invention may further contain about 0.63% to about 1.5% hydroxypropyl methylcellulose (HPMC).
[0038] In certain embodiments, the pharmaceutical composition of the present invention further comprises a penetration enhancer, such as a fatty acid, bile salt, chelating agent, surfactant, and a non-surfactant, such as an unsaturated cyclic urea, 1-alkyl alkanone, 1-alkenylazacyclo-alakanone, or a steroidal anti-inflammatory agent.
[0039] In some embodiments, the composition is contained in a capsule, which may be coated by a method well known in the art. Capsules used for non-parental delivery may include formulations well known in the art.
[0040] In some embodiments, the capsules may include single-piece capsules, two-piece capsules, transparent capsules, opaque capsules, untransparent capsules, opaque capsules, sustained-release capsules, continuous-release capsules, standard-release capsules, rapid-release capsules, rapid-release capsules, hard-shell capsules, soft-gel capsules, gel capsules, hard gelatin capsules, soft gelatin capsules, animal-derived capsules, vegetarian capsules, polysaccharide capsules, cellulose capsules, mucopolysaccharide capsules, tapioca capsules, hydroxypropyl methylcellulose (HPMC) capsules, pullulan capsules, enteric-coated capsules, uncoated capsules, coated capsules, and capsules containing titanium dioxide, fatty acids, waxes, shellac, plastics, plasticizers, glycerin, sorbitol, vegetable fibers, additives, preservatives, colorants, or any combination thereof.
[0041] Furthermore, multi-compartment capsules, lipid-coated capsules, water-permeable capsules, capsules with controlled-release properties, capsules with multi-stage drug delivery systems, or any combination thereof may also be used in the formulation of the composition of the present invention.
[0042] The formulations of the present invention may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohol, or solutions of nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents, and other suitable additives. Furthermore, the formulations may include pharmaceutically acceptable organic or inorganic carriers that do not react adversely with the components of the mammalian exosome composition and are suitable for non-parenteral administration. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycol, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, and polyvinylpyrrolidone. The formulations can be sterilized and, if desired, can be mixed with auxiliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts that affect osmotic pressure, buffers, colorants, flavorings, aromatics, or any combination thereof. The aqueous suspension may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, and / or dextran. The suspension may also contain stabilizers.
[0043] In some embodiments, the solution according to the present invention essentially consists of a nucleoside moiety. In some embodiments, the present invention provides a pharmaceutical composition comprising at least one nucleoside moiety, such as a nucleoside, nucleotide, or nucleic acid, in a solution or emulsion. The nucleic acid may be a ribozyme, PNA, or aptamer, but is preferably an oligonucleotide. In some embodiments, the solution according to the present invention essentially consists of a nucleoside moiety and a solvent, such as physiological saline or cocoa butter.
[0044] In some embodiments, the solution according to the present invention essentially consists of a nucleoside moiety and a solvent, such as physiological saline or cocoa butter.
[0045] The formulations may be conveniently provided in unit dosage forms, or they may be prepared according to prior art well known in the pharmaceutical industry. Such arts include the step of combining the active ingredient with a pharmaceutical carrier or excipient. Generally, formulations are prepared by uniformly and tightly combining the active ingredient with a liquid carrier, a fine powder solid carrier, or both, and then shaping the product as needed.
[0046] Non-parental administration of the compositions of the present invention may involve suppositories. Suppositories are well known in the art. They are usually formulated to be solid at room temperature, with a melting point lower than the normal human body temperature of 36 or 37°C. Therefore, it is common to formulate suppositories using a fatty base such as cocoa butter that meets the above melting point criterion. In some embodiments, the suppository form may include further excipients such as binders and adhesives, lubricants, disintegrants, colorants and fillers, but are not limited to the following. In some embodiments, the suppository includes any combination of the above base substances.
[0047] Non-parental administration of the composition of the present invention may include a coating material that can alter the delivery of the therapeutic agent. The coating material can facilitate administration without interfering with the pharmacological activity of the product.
[0048] In some embodiments, suppositories containing one or more fatty acids are coated with a fat or oily base, such as cocoa butter, hard fats and hydrogenated vegetable oils, waxes, water-soluble or water-miscible bases, such as polyethylene glycol, glycol-surfactant combinations and polyoxyethylene sorbitan fatty acid esters, and combinations thereof. Furthermore, the coated suppositories may be in the form of rectal capsules in which a core containing free fatty acids is covered with a water-soluble compound such as gelatin.
[0049] In some embodiments, the composition may further comprise cocoa butter, coconut oil, glycerin gelatin, hydrogenated oil, polyethylene glycol (PEG), or fatty acid esters of PEG.
[0050] To reduce discomfort during drug action and defecation, it may be convenient to include excipient oil components such as triacylglyceride oil in the suppository form of the present invention, and the overall composition of the dosage form is configured to have a suitable and desirable melting point.
[0051] The compositions of the present invention encompass any pharmaceutically acceptable compound that, when administered to an organism, can provide (directly or indirectly) its biologically active metabolites or residues. Accordingly, this disclosure also relates, for example, to “prodrugs” and “pharmaceutically acceptable salts” of the compounds of the present invention, as well as other bioequivalents.
[0052] Furthermore, a method for treating an animal is also provided, comprising administering to the animal a therapeutically effective amount of the pharmaceutical composition according to the present invention. The composition can be administered via non-parental routes, such as buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, pulmonary, or urethral routes. In a preferred embodiment, the composition of the present invention is administered via the vagina or rectum by enema or suppository.
[0053] use Described herein are systems useful for the non-parental oral, transrectal, or transvaginal delivery of exosomes to the target gastrointestinal tract, skin, eyes, pulmonary tract, urethra, vagina, or circulatory system. These systems can be used to deliver exosomes across barriers to the blood or lymphatic system via the rectal or vaginal pathway. The systems described herein can be used to deliver therapeutic doses of mammalian exosomes to a target. In certain embodiments, the systems are used to deliver therapeutic doses of human exosomes to a human subject. In certain embodiments, the systems are used to deliver therapeutic doses of human exosomes to a human subject diagnosed with, suspected of having, or at risk of having, a disease or disorder.
[0054] In certain embodiments, the system and mammalian exosome composition deliver a therapeutic dose of exosomes to the colon (e.g., large intestine) of an individual diagnosed with, suspected of having, or at risk of having, a disease or disorder. In certain embodiments, the system delivers a therapeutic dose of exosomes to the small intestine of an individual diagnosed with, suspected of having, or at risk of having, a disease or disorder. In certain embodiments, the system delivers a therapeutic dose of exosomes to the vagina of an individual diagnosed with, suspected of having, or at risk of having, a disease or disorder. In certain embodiments, the system delivers a therapeutic dose of exosomes to the ileum of an individual diagnosed with, suspected of having, or at risk of having, a disease or disorder. In certain embodiments, the system delivers a therapeutic dose of exosomes to the duodenum of an individual diagnosed with, suspected of having, or at risk of having, a disease or disorder. In certain embodiments, the system delivers a therapeutic dose of exosomes to the jejunum of an individual diagnosed with, suspected of having, or at risk of having, a disease or disorder. In certain embodiments, the system delivers a therapeutic dose of exosomes to the vagina of an individual diagnosed with, suspected of having, or at risk of having, a disease or disorder. In certain embodiments, the individual is a human individual, and the exosomes are human exosomes.
[0055] The non-parenteral, oral, transrectal, or transvaginal systems used herein are useful for delivering therapeutic doses of mammalian exosomes to farmed animals for veterinary use. In certain embodiments, the system delivers therapeutic doses of canine exosomes to dogs. In certain embodiments, the system delivers therapeutic doses of canine exosomes to dogs suffering from inflammatory bowel disease. In certain embodiments, the system delivers therapeutic doses of feline exosomes to cats. In certain embodiments, the system delivers therapeutic doses of bovine exosomes to cattle. The transrectal or transvaginal systems described herein may also be used in combination with other therapies administered transrectally or transvaginally to animals. In certain embodiments, the system containing canine exosomes may be mixed with food and delivered to dogs. In certain embodiments, the system containing feline exosomes may be mixed with food and delivered to cats. In certain embodiments, the system containing bovine exosomes may be mixed with food or nutritional feed and delivered to cattle.
[0056] In certain embodiments, the mammalian exosome delivery system and compositions are intended for use in the treatment of inflammatory disorders or autoimmune disorders in humans. In certain embodiments, the inflammatory disorder or autoimmune disorder is a gastrointestinal inflammatory disorder or autoimmune disorder. In certain embodiments, the gastrointestinal inflammatory disorder or autoimmune disorder includes inflammatory bowel disease or Crohn's disease. In certain embodiments, the gastrointestinal inflammatory disorder or autoimmune disorder includes Crohn's disease.
[0057] In certain embodiments, the mammalian exosome delivery system and compositions are intended for use in the treatment of inflammatory or autoimmune disorders in animals. In certain embodiments, the inflammatory or autoimmune disorder is a gastrointestinal inflammatory or autoimmune disorder. In certain embodiments, the animal is one or more of the following: dog, cattle, cattle, pig, horse, or sheep.
[0058] Exosomes The exosomes described herein are derived from mammalian cells and are isolated and purified according to methods known in the art.
[0059] The non-parenteral, oral, transrectal, or transvaginal delivery systems and compositions of mammalian exosomes described herein are useful for delivering exosomes to the digestive tract of a subject. In certain embodiments, the exosomes include eukaryotic exosomes. In certain embodiments, the exosomes include eukaryotic exosomes lacking a cell wall. In certain embodiments, the exosomes include mammalian exosomes. In certain embodiments, the exosomes include human exosomes. In certain embodiments, the exosomes include exosomes of domesticated animals selected from cats, dogs, pigs, sheep, horses, cattle, goats, yaks, and any combination thereof. The exosomes contained in the non-parenteral, oral, transrectal, or transvaginal delivery systems are capable of producing a therapeutic effect and stopping, reducing, or relieving symptoms of at least one disease associated with the subject that the subject has been diagnosed with or is suspected of having. In certain embodiments, the disease is a disease of the digestive tract selected from Crohn's disease or inflammatory bowel disease. In certain embodiments, the exosomes do not include prokaryotic exosomes.
[0060] Stem cells include certain types of cells useful for producing exosomes for inclusion in the non-parenteral, oral, transrectal, or transvaginal delivery systems described herein. In certain embodiments, the transrectal or transvaginal delivery system includes multiple stem exosomes derived from or isolated and purified from stem cells. In certain embodiments, stem cells include embryonic stem cells, pluripotent stem cells, adult stem cells, induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, myoblasts, fibroblasts, hepatic stem cells, renal stem cells, cardiac stem cells, or intestinal stem cells, or mixtures thereof. In certain embodiments, cells include embryonic stem cells. In certain embodiments, cells include mesenchymal stem cells. In certain embodiments, cells include type I (pro-inflammatory) mesenchymal stem cells. In certain embodiments, cells include type II (anti-inflammatory) mesenchymal stem cells. In certain embodiments, cells include pluripotent stem cells or induced pluripotent stem cells. Type I or type II mesenchymal stem cells can be produced using TLR4 or TLR3 agonists, respectively. Methods for producing type 1 or type 2 mesenchymal stem cells are described in U.S. Patent Application Publication 2014 / 0017787 or International Publication 2016053758(A1), both of which are incorporated herein by reference. In certain embodiments, type 2 MSCs express higher levels of CXCL9 than MSC2s that are not induced by TLR3.
[0061] Other types of cells useful for producing exosomes to be included in the non-parenteral, oral, transrectal, or transvaginal delivery systems described herein are immune cells. In certain embodiments, the non-parenteral, oral, transrectal, or transvaginal delivery system comprises a plurality of immune cells. In certain embodiments, the immune cells include B cells (e.g., CD19+ cells), T cells (e.g., CD3+ cells), CD8+ T cells, CD4+ T cells, NK cells, dendritic cells, or macrophage cells. In certain embodiments, the immune cells include T cells. In certain embodiments, the T cells include T cells having a regulatory T cell phenotype, expressing and secreting IL-10, expressing and secreting TGF-β, or expressing the transcription factor FoxP3. In certain embodiments, the immune cells include NK cells. In certain embodiments, the immune cells include macrophages. In certain embodiments, the macrophages include M1-type (pro-inflammatory) macrophages. In certain embodiments, the macrophages include M2-type (suppressor) macrophages.
[0062] In certain embodiments, the non-parenteral, oral, transrectal, or transvaginal delivery systems and compositions of mammalian exosomes described herein include a mixture of different types of exosomes (e.g., exosomes from different types of cells). In certain embodiments, the mixture includes 2, 3, 4, 5, 6, 7, 8, 9, or more different types of exosomes. In certain embodiments, the mixture includes stem cell exosomes and immune cell exosomes. In certain embodiments, the mixture includes different stem cell exosomes. In certain embodiments, the mixture includes different types of immune exosomes. In certain embodiments, the mixture includes stem cell exosomes and immune cell exosomes. The mixture can be in any ratio preferred for therapeutic treatment. In certain embodiments, two different cell types are included, and the ratio of the first type to the second type is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, or 1:9.
[0063] The non-parental, oral, transrectal, or transvaginal delivery systems and compositions of mammalian exosomes described herein contain therapeutic doses of exosomes. In certain embodiments, therapeutic doses of exosomes include
[0064] matrix The exosomes and mammalian exosome compositions currently described for non-parenteral, oral, transrectal, or transvaginal delivery systems include or are embedded in a matrix, gel, or excipient. The matrix serves to protect the exosomes from dehydration, osmotic stress, pH stress, protease degradation, and other stresses present in the digestive system. In certain embodiments, the exosomes are embedded in or suspended within the matrix. In certain embodiments, the matrix includes agar. In certain embodiments, the matrix includes methylcellulose. In certain embodiments, the matrix includes alginate. In certain embodiments, the matrix includes methylcellulose and alginate. In certain embodiments, the matrix includes approximately equal amounts of methylcellulose and alginate. In certain embodiments, the matrix includes a hydrogel. Suitable hydrogels include those derived from collagen, hyaluronic acid, hyaluronan, fibrin, alginate, agarose, chitosan, and combinations thereof. In other embodiments, suitable hydrogels are synthetic polymers. In further embodiments, suitable matrices for embedding exosomes include those derived from poly(acrylic acid) and its derivatives, poly(ethylene oxide) and its copolymers, poly(vinyl alcohol), polyphosphazene, and combinations thereof. In various specific embodiments, the confinement material is selected from hydrogels, NovoGel®, agarose, alginic acid, gelatin, Matrigel®, hyaluronan, poloxamer, peptide hydrogels, poly(isopropyl n-polyacrylamide), polyethylene glycol diacrylate (PEG-DA), hydroxyethyl methacrylate, polydimethylsiloxane, polyacrylamide, poly(lactic acid), or combinations thereof.
[0065] In certain embodiments, the matrix comprises approximately equal amounts of alginate gel and methylcellulose.
[0066] In certain embodiments, the matrix comprises exosomes mixed with alginate gel and methylcellulose in predetermined ratios. In certain embodiments, the ratio of alginate gel to methylcellulose in the matrix is about 1:0.1, about 1:0.2, about 1:0.3, about 1:0.4, about 1:0.5, about 1:0.6, about 1:0.7, about 1:0.8, about 1:0.9, about 1:1, about 1:1.1, about 1:1.2, about 1:1.3, about 1:1.4, about 1:1.5, about 1:1.6, about 1:1.7, about 1:1.8, about 1:1.9, or about 1:2. In certain embodiments, the ratio of methylcellulose in the matrix to the alginate gel is about 1:0.1, about 1:0.2, about 1:0.3, about 1:0.4, about 1:0.5, about 1:0.6, about 1:0.7, about 1:0.8, about 1:0.9, about 1:1, about 1:1.1, about 1:1.2, about 1:1.3, about 1:1.4, about 1:1.5, about 1:1.6, about 1:1.7, about 1:1.8, about 1:1.9, or about 1:2.
[0067] Alternatively, in certain embodiments, this mixture of alginate gel and methylcellulose may contain different concentrations of methylcellulose. In certain embodiments, the concentration of alginate gel is about 0.5% to about 5.0%. In certain embodiments, the concentration of alginate gel is about 0.5% to about 4.0%. In certain embodiments, the concentration of alginate gel is about 0.5% to about 3.0%. In certain embodiments, the concentration of alginate gel is at least about 0.5%. In certain embodiments, the concentration of alginate gel is up to about 3.0%. In certain embodiments, the concentration of the alginate gel is about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0%. In certain embodiments, the concentration of the alginate gel is at least about 0.5%, at least about 0.6%, at least about 0.7%, at least about 0.8%, at least about 0.9%, at least about 1.0%, at least about 1.1%, at least about 1.2%, at least about 1.3%, or at least about 1.4%. In certain embodiments, the concentration of the alginate gel is up to about 3.0%, up to about 2.9%, up to about 2.8%, up to about 2.7%, up to about 2.6%, up to about 2.5%, up to about 2.4%, up to about 2.3%, up to about 2.2%, up to about 2.1%, up to about 2.0%, up to about 1.9%, up to about 1.8%, up to about 1.7%, up to about 1.6%, or up to about 1.5%.In certain embodiments, the concentration of the alginate gel is approximately 0.5% to approximately 0.7%, approximately 0.5% to approximately 0.9%, approximately 0.5% to approximately 1.1%, approximately 0.5% to approximately 1.3%, approximately 0.5% to approximately 1.5%, approximately 0.5% to approximately 1.7%, approximately 0.5% to approximately 1.9%, approximately 0.5% to approximately 2.1%, approximately 0.5% to approximately 2.5%, approximately 0.5% to approximately 2.7%, approximately 0.5% to approximately 2.9%, approximately 0.7% to approximately 0.9%, approximately 0.7% to approximately 1.1%, approximately 0.7% to approximately 1.3%, approximately 0.7% to approximately 1.5%, and approximately 0. 0.7%~approximately 1.7%, approximately 0.7%~approximately 1.9%, approximately 0.7%~approximately 2.1%, approximately 0.7%~approximately 2.5%, approximately 0.7%~approximately 2.7%, approximately 0.7%~approximately 2.9%, approximately 0.9%~approximately 1.1%, approximately 0.9%~approximately 1.3%, approximately 0.9%~approximately 1.5%, approximately 0.9%~approximately 1.7%, approximately 0.9%~approximately 1.9%, approximately 0.9%~approximately 2.1%, approximately 0.9%~approximately 2.5%, approximately 0.9%~approximately 2.7%, approximately 0.9%~approximately 2.9%, approximately 1.1%~approximately 1.3%, approximately 1.1%~approximately 1.5%, approximately 1. 1% to approximately 1.7%, approximately 1.1% to approximately 1.9%, approximately 1.1% to approximately 2.1%, approximately 1.1% to approximately 2.5%, approximately 1.1% to approximately 2.7%, approximately 1.1% to approximately 2.9%, approximately 1.3% to approximately 1.5%, approximately 1.3% to approximately 1.7%, approximately 1.3% to approximately 1.9%, approximately 1.3% to approximately 2.1%, approximately 1.3% to approximately 2.5%, approximately 1.3% to approximately 2.7%, approximately 1.3% to approximately 2.9%, approximately 1.5% to approximately 1.7%, approximately 1.5% to approximately 1.9%, approximately 1.5% to approximately 2.1%, approximately 1.5% to approximately 2.5%, approximately 1.5 The percentages are approximately 2.7%, 2.9%, 1.7%, 2.1%, 2.5%, 2.7%, 2.7%, 2.9%, 2.1%, 2.5%, 2.7%, 2.7%, 2.5%, 2.5%, 2.7%, 2.9%, 2.1%, 2.5%, 2.7%, 2.9%, 2.1%, 2.5%, 2.1%, 2.7%, 2.1%, 2.9%, 2.5%, 2.7%, 2.1%, 2.9%, 2.5%, 2.9%, or 2.7%.
[0068] In certain embodiments, the concentration of the alginate gel is approximately 0.1% to approximately 1%. In certain embodiments, the concentration of the alginate gel is approximately 0.1% to 0.25%, 0.1% to 0.33%, 0.1% to 0.5%, 0.1% to 0.67%, 0.1% to 0.75%, 0.1% to 0.8%, 0.1% to 0.9%, 0.1% to 1%, 0.25% to 0.33%, 0.25% to 0.5%, 0.25% to 0.67%, 0.25% to 0.75%, 0.25% to 0.8%, 0.25% to 0.9%, 0.25% to 1%, 0.33% to 0.5%, and 0.33% to 0.67%. The percentages are approximately 0.33% to 0.75%, 0.33% to 0.8%, 0.33% to 0.9%, 0.33% to 1%, 0.5% to 0.67%, 0.5% to 0.75%, 0.5% to 0.8%, 0.5% to 0.9%, 0.5% to 1%, 0.67% to 0.75%, 0.67% to 0.8%, 0.67% to 0.9%, 0.67% to 1%, 0.75% to 0.8%, 0.75% to 0.9%, 0.75% to 1%, 0.8% to 0.9%, 0.8% to 1%, or 0.9% to 1%. In certain embodiments, the concentration of the alginate gel is about 0.1%, about 0.25%, about 0.33%, about 0.5%, about 0.67%, about 0.75%, about 0.8%, about 0.9%, or about 1%. In certain embodiments, the concentration of the alginate gel is at least about 0.1%, about 0.25%, about 0.33%, about 0.5%, about 0.67%, about 0.75%, about 0.8%, or about 0.9%. In certain embodiments, the concentration of the alginate gel is at most about 0.25%, about 0.33%, about 0.5%, about 0.67%, about 0.75%, about 0.8%, about 0.9%, or about 1%.
[0069] In certain embodiments, the concentration of methylcellulose is approximately 0.5% to approximately 3.0%. In certain embodiments, the concentration of methylcellulose is at least approximately 0.5%. In certain embodiments, the concentration of methylcellulose is up to approximately 3.0%. In certain embodiments, the concentration of methylcellulose is approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9%, approximately 1.0%, approximately 1.1%, approximately 1.2%, approximately 1.3%, approximately 1.4%, approximately 1.5%, approximately 1.6%, approximately 1.7%, approximately 1.8%, approximately 1.9%, approximately 2.0%, approximately 2.1%, approximately 2.2%, approximately 2.3%, approximately 2.4%, approximately 2.5%, approximately 2.6%, approximately 2.7%, approximately 2.8%, approximately 2.9%, or approximately 3.0%. In certain embodiments, the concentration of methylcellulose is at least about 0.5%, at least about 0.6%, at least about 0.7%, at least about 0.8%, at least about 0.9%, at least about 1.0%, at least about 1.1%, at least about 1.2%, at least about 1.3%, or at least about 1.4%. In certain embodiments, the concentration of methylcellulose is up to about 3.0%, up to about 2.9%, up to about 2.8%, up to about 2.7%, up to about 2.6%, up to about 2.5%, up to about 2.4%, up to about 2.3%, up to about 2.2%, up to about 2.1%, up to about 2.0%, up to about 1.9%, up to about 1.8%, up to about 1.7%, up to about 1.6%, or up to about 1.5%.In certain embodiments, the concentration of methylcellulose is approximately 0.5% to approximately 0.7%, approximately 0.5% to approximately 0.9%, approximately 0.5% to approximately 1.1%, approximately 0.5% to approximately 1.3%, approximately 0.5% to approximately 1.5%, approximately 0.5% to approximately 1.7%, approximately 0.5% to approximately 1.9%, approximately 0.5% to approximately 2.1%, approximately 0.5% to approximately 2.5%, approximately 0.5% to approximately 2.7%, approximately 0.5% to approximately 2.9%, approximately 0.7% to approximately 0.9%, approximately 0.7% to approximately 1.1%, approximately 0.7% to approximately 1.3%, approximately 0.7% to approximately 1.5%, and approximately 0. 0.7%~approximately 1.7%, approximately 0.7%~approximately 1.9%, approximately 0.7%~approximately 2.1%, approximately 0.7%~approximately 2.5%, approximately 0.7%~approximately 2.7%, approximately 0.7%~approximately 2.9%, approximately 0.9%~approximately 1.1%, approximately 0.9%~approximately 1.3%, approximately 0.9%~approximately 1.5%, approximately 0.9%~approximately 1.7%, approximately 0.9%~approximately 1.9%, approximately 0.9%~approximately 2.1%, approximately 0.9%~approximately 2.5%, approximately 0.9%~approximately 2.7%, approximately 0.9%~approximately 2.9%, approximately 1.1%~approximately 1.3%, approximately 1.1%~approximately 1.5%, approximately 1. 1% to approximately 1.7%, approximately 1.1% to approximately 1.9%, approximately 1.1% to approximately 2.1%, approximately 1.1% to approximately 2.5%, approximately 1.1% to approximately 2.7%, approximately 1.1% to approximately 2.9%, approximately 1.3% to approximately 1.5%, approximately 1.3% to approximately 1.7%, approximately 1.3% to approximately 1.9%, approximately 1.3% to approximately 2.1%, approximately 1.3% to approximately 2.5%, approximately 1.3% to approximately 2.7%, approximately 1.3% to approximately 2.9%, approximately 1.5% to approximately 1.7%, approximately 1.5% to approximately 1.9%, approximately 1.5% to approximately 2.1%, approximately 1.5% to approximately 2.5%, approximately 1.5 The percentages are approximately 2.7%, 2.9%, 1.7%, 2.1%, 2.5%, 2.7%, 2.7%, 2.9%, 2.1%, 2.5%, 2.7%, 2.7%, 2.5%, 2.5%, 2.7%, 2.9%, 2.1%, 2.5%, 2.7%, 2.9%, 2.1%, 2.5%, 2.1%, 2.7%, 2.1%, 2.9%, 2.5%, 2.7%, 2.1%, 2.9%, 2.5%, 2.9%, or 2.7%.
[0070] In certain embodiments, the concentration of methylcellulose l is approximately 0.1% to approximately 1%. In certain embodiments, the concentration of methylcellulose l is approximately 0.1% to approximately 0.25%, approximately 0.1% to approximately 0.33%, approximately 0.1% to approximately 0.5%, approximately 0.1% to approximately 0.67%, approximately 0.1% to approximately 0.75%, approximately 0.1% to approximately 0.8%, approximately 0.1% to approximately 0.9%, approximately 0.1% to approximately 1%, approximately 0.25% to approximately 0.33%, approximately 0.25% to approximately 0.5%, approximately 0.25% to approximately 0.67%, approximately 0.25% to approximately 0.75%, approximately 0.25% to approximately 0.8%, approximately 0.25% to approximately 0.9%, approximately 0.25% to approximately 1%, approximately 0.33% to approximately 0.5%, approximately 0.33% to approximately 0. The percentages are 67%, approximately 0.33% to 0.75%, approximately 0.33% to 0.8%, approximately 0.33% to 0.9%, approximately 0.33% to 1%, approximately 0.5% to 0.67%, approximately 0.5% to 0.75%, approximately 0.5% to 0.8%, approximately 0.5% to 0.9%, approximately 0.5% to 1%, approximately 0.67% to 0.75%, approximately 0.67% to 0.8%, approximately 0.67% to 0.9%, approximately 0.67% to 1%, approximately 0.75% to 0.8%, approximately 0.75% to 0.9%, approximately 0.75% to 1%, approximately 0.8% to 0.9%, approximately 0.8% to 1%, or approximately 0.9% to 1%. In certain embodiments, the concentration of methylcellulose l is about 0.1%, about 0.25%, about 0.33%, about 0.5%, about 0.67%, about 0.75%, about 0.8%, about 0.9%, or about 1%. In certain embodiments, the concentration of methylcellulose l is at least about 0.1%, about 0.25%, about 0.33%, about 0.5%, about 0.67%, about 0.75%, about 0.8%, or about 0.9%. In certain embodiments, the concentration of methylcellulose l is at most about 0.25%, about 0.33%, about 0.5%, about 0.67%, about 0.75%, about 0.8%, about 0.9%, or about 1%.
[0071] In some embodiments, the matrix comprises exosomes mixed with a matrix of approximately 0.5% to 3.0% alginate gel and approximately 0.5% to 3.0% methylcellulose. The cell gel mixture is then transferred to capsules coated with a lipophilic or hydrophilic film. In certain embodiments, the capsules are coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0072] In some embodiments, the matrix comprises mammalian exosomes mixed with a matrix of approximately 1.5% alginate gel and approximately 1.5% methylcellulose. The exosome gel mixture is then transferred to capsules coated with a lipophilic or hydrophilic film. In certain embodiments, the capsules are coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0073] In some embodiments, the matrix comprises mammalian exosomes suspended in a mixture of approximately 0.5% to approximately 3.0% alginate gel and approximately 0.5% to approximately 3.0% methylcellulose, within capsules coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0074] In some embodiments, the matrix comprises mammalian exosomes suspended in a mixture of approximately 1.0% to approximately 2.5% alginate gel and approximately 1.0% to approximately 2.5% methylcellulose, within capsules coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0075] In some embodiments, the matrix comprises mammalian exosomes suspended in a mixture of approximately 1.0% to approximately 2.0% alginate gel and approximately 1.0% to approximately 2.0% methylcellulose, within capsules coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0076] In some embodiments, the matrix comprises mammalian exosomes suspended in a mixture of about 1.2% to about 1.8% alginate gel and about 1.2% to about 1.8% methylcellulose, within capsules coated with a methyl methacrylate-methacrylate copolymer (1:1).
[0077] In some embodiments, the matrix comprises mammalian exosomes suspended in a mixture of approximately 1.4% to 1.6% alginate gel and approximately 1.4% to 1.6% methylcellulose, within capsules coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0078] In some embodiments, the matrix comprises mammalian exosomes suspended in a mixture of approximately 0.25% to approximately 0.75% alginate gel and approximately 0.25% to approximately 0.75% methylcellulose, within capsules coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0079] In some embodiments, the matrix comprises mammalian exosomes suspended in a mixture of approximately 0.1% to approximately 0.9% alginate gel and approximately 0.1% to approximately 0.9% methylcellulose, within capsules coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0080] In some embodiments, the matrix comprises mammalian exosomes suspended in a mixture of approximately 1.5% alginate gel and approximately 1.5% methylcellulose within capsules coated with a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the mammalian exosomes comprise mesenchymal stem cell exosomes.
[0081] In certain embodiments, the matrix comprises a predetermined concentration of exosomes and agar. In a specific embodiment, the concentration of agar in the matrix is approximately 0.1% w / v to 10% w / v, approximately 0.1% w / v to 8% w / v, approximately 0.1% w / v to 5% w / v, approximately 0.1% w / v to 4% w / v, approximately 0.1% w / v to 3% w / v, approximately 0.1% w / v to 2% w / v, approximately 0.1% w / v to 1% w / v, approximately 0.2% w / v to 10% w / v, approximately 0.2% w / v to 8% w / v, approximately 0.2% w / v to 5% w / v, approximately 0.2% w / v to 4% w / v, approximately 0.2% w / v to 3% w / v, approximately 0.2% w / v to 2% w / v, approximately 0.2% w / v to 1% w / v, and approximately 0.4% w / v. w / v ~ approximately 10% w / v, approximately 0.4% w / v ~ approximately 8% w / v, approximately 0.4% w / v ~ approximately 5% w / v, approximately 0.4% w / v ~ approximately 4% w / v, approximately 0.4% w / v ~ approximately 3% w / v, approximately 0.4% w / v ~ approximately 2% w / v, approximately 0.4% w / v ~ approximately 1% w / v, approximately 0.5% w / v ~ approximately 10% w / v, approximately 0.5% w / v ~ approximately 8% w / v, approximately 0.5% w / v ~ approximately 5% w / v, approximately 0.5% w / v ~ approximately 4% w / v, approximately 0.5% w / v ~ approximately 3% w / v, approximately 0.5% w / v ~ approximately 2% w / v, approximately 0.5% w / v ~ approximately 1% w / v. In certain embodiments, the agar concentration in the matrix is approximately 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0%. In certain embodiments, the agar concentration in the matrix is approximately 1.0%, 2.0%, 3.0%, 4.0%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, or 10%.
[0082] The matrices described herein have a predetermined viscosity. In further embodiments, the exosome-containing matrix is characterized by having a viscosity of about 500 to 1,000,000 centipoise, about 1,000 to 1,000,000 centipoise, about 1,000 to 500,000 centipoise, about 10,000 to 500,000 centipoise, about 10,000 to 400,000 centipoise, about 10,000 to 3,000,000 centipoise, about 100,000 to 1,000,000 centipoise, or about 500,000 to 1,000,000 centipoise.
[0083] In certain embodiments, the matrix comprises extracellular matrix proteins such as collagen or fibrin; carbohydrates such as glucose, dextrose, or sucrose; fibers such as cellulose; vitamins or minerals; and additional molecules such as buffers, isotonic solutions, or amino acids.
[0084] The exosomes of this disclosure can be characterized in a variety of ways. In certain embodiments, the exosomes comprise proteins or polypeptides selected from a list consisting of CD81, CD63, CD9, HSP60, HSP70, HSP90, VEGF, PGE2, and combinations thereof. Exosome particles can be characterized by standard methods known in the art, such as flow cytometry using specific antibodies compared to isotype control antibodies. In certain embodiments, the exosomes may be characterized by a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in CD81 protein compared to isotype control antibodies. In certain embodiments, the exosomes may be characterized by a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in CD63 protein compared to isotype control antibodies. In certain embodiments, the exome may be characterized by a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in CD9 protein compared to the isotype control antibody. In certain embodiments, the exome may be characterized by a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in HSP60 protein compared to the isotype control antibody. In certain embodiments, the exome may be characterized by a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in HSP70 protein compared to the isotype control antibody. In certain embodiments, the exome may be characterized by a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in HHSP90 protein compared to the isotype control antibody. In certain embodiments, the exome may be characterized by a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in VEGF protein compared to the isotype control antibody. In certain embodiments, the exome may be characterized by a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold increase in PGE2 protein compared to the isotype control antibody.
[0085] Furthermore, the compositions described herein allow for the recovery of a larger number of exosomes after incubation at pH 1.2 for 2 hours. In certain embodiments, 30%, 40%, 50%, 60%, 70%, 80%, and 90% or more of intact exosomes can be recovered after incubation at pH 1.2 for 2 hours. In certain embodiments, 30% or more of intact exosomes can be recovered after incubation at pH 1.2 for 2 hours. In certain embodiments, 40% or more of intact exosomes can be recovered after incubation at pH 1.2 for 2 hours. In certain embodiments, 50% or more of intact exosomes can be recovered after incubation at pH 1.2 for 2 hours. In certain embodiments, 60% or more of intact exosomes can be recovered after incubation at pH 1.2 for 2 hours. Intact exosomes can be counted and confirmed under a microscope.
[0086] coating The oral delivery systems described herein include a coating prepared to dissolve at a specific pH. In the case of two-phase delivery, the oral delivery system includes two coatings prepared to dissolve at different pH levels. In certain embodiments, the coatings are prepared to dissolve at approximately pH 5.5 to approximately 6.0 for targeting the duodenum; at approximately pH 7.3 to approximately 8.0 for targeting the ileum; or at approximately pH 5.5 to approximately 6.5 for targeting the colon. In certain embodiments, the coatings are prepared to dissolve at approximately pH 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. In certain embodiments, for two-phase delivery, one capsule is prepared with a pH of approximately 7.3 to 8.0 to target the ileum; and one capsule is prepared with a pH of approximately 5.5 to 6.5 to target the colon. In certain embodiments, for two-phase delivery, one capsule is prepared with a pH of approximately 5.5 to 6.0 to target the duodenum; and one capsule is prepared with a pH of approximately 5.5 to 6.5 to target the colon. In certain embodiments, for two-phase delivery, one capsule is prepared with a pH of approximately 5.5 to 6.0 to target the duodenum; and one capsule is prepared with a pH of approximately 7.3 to 8.0 to target the ileum.
[0087] Furthermore, exosomes or preparations thereof, and enteric-coated exosome preparations containing enteric-coated materials; and pharmaceutically acceptable carriers or excipients thereof are also envisioned. Enteric-coated materials refer to polymers that are substantially insoluble in the acidic environment of the stomach and primarily soluble in intestinal fluid at a specific pH. The small intestine is part of the gastrointestinal tract (intestine) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum. The pH of the duodenum is approximately 5.5, the pH of the jejunum is approximately 6.5, and the pH of the distal ileum is approximately 7.5. Therefore, enteric-coated materials will not dissolve at pH levels of approximately 5.0, 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 8.2, 8.4, 8.6, 8.8, 9.0, 9.2, 9.4, 9.6, 9.8, or up to approximately 10.0. Exemplary enteric materials that may be included in the oral delivery systems and compositions of mammalian exosomes described herein include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methyl methacrylate and methyl methacrylate, copolymer of methyl acrylate, methyl methacrylate and methacrylic acid, copolymer of methyl vinyl ether and maleic anhydride (Gantrez ES series), ethyl methyl acrylate-methyl methacrylate-chlorotrimethylammonium ethyl acrylate copolymer, zein, shellac, and copal. Examples include natural resins such as colophonium, and several commercially available enteric-coated dispersion systems (e.g., Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D, Estacryl 30D, Coateric, and Aquateric).The solubility of each of the above substances is either known or can be easily determined in vitro.
[0088] A two-phase capsule containing mammalian exosomes comprises first and second enteric coatings. In certain embodiments, the first enteric coating comprises a copolymer of methacrylic acid, methyl methacrylate, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, cellulose acetate trimellitate, sodium alginate, or zein. In certain embodiments, the second enteric coating comprises a copolymer of methacrylic acid, methyl methacrylate, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, cellulose acetate trimellitate, sodium alginate, or zein. In certain embodiments, the first enteric coating comprises a copolymer of methacrylic acid. In certain embodiments, the second enteric coating comprises a copolymer of methacrylic acid.
[0089] In certain embodiments, the enteric coating of the mammalian exosome composition described herein comprises a methyl methacrylate-methacrylate copolymer (1:1).
[0090] In certain embodiments, the gel, matrix, or excipient, together with the enteric coating, maintains the viability of the first plurality of mammalian exosomes and / or the second plurality of mammalian exosomes at a viability of approximately 80–85%. In certain embodiments, the gel, matrix, or excipient maintains the viability of the first plurality of mammalian exosomes and / or the second plurality of exosomes at a viability of approximately 50%, 60%, 70%, or greater than 80% at 24°C for at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
[0091] In certain embodiments, the gel, matrix, along with an enteric coating or excipient, is subjected to a T-coating for approximately 0.4 to 0.6 hours. max The following is provided: In a particular embodiment, the gel, matrix, or excipient is used for approximately 0.4 hours, approximately 0.41 hours, approximately 0.42 hours, approximately 0.43 hours, approximately 0.44 hours, approximately 0.45 hours, approximately 0.46 hours, approximately 0.47 hours, approximately 0.48 hours, approximately 0.49 hours, approximately 0.50 hours, approximately 0.51 hours, approximately 0.52 hours, approximately 0.53 hours, approximately 0.54 hours, approximately 0.55 hours, approximately 0.56 hours, approximately 0.57 hours, approximately 0.58 hours, approximately 0.59 hours, or approximately 0.60 hours of T max Provides a gel, matrix, or excipient for at least about 0.4 hours, at least about 0.4 hours, at least about 0.42 hours, at least about 0.43 hours, at least about 0.44 hours, or at least about 0.45 hours of T max Provides a gel, matrix, or excipient for a maximum of approximately 0.46 hours, approximately 0.47 hours, approximately 0.48 hours, approximately 0.49 hours, approximately 0.50 hours, approximately 0.51 hours, approximately 0.52 hours, approximately 0.53 hours, approximately 0.54 hours, approximately 0.55 hours, approximately 0.56 hours, approximately 0.57 hours, approximately 0.58 hours, approximately 0.59 hours, or approximately 0.60 hours of T max To provide.
[0092] The non-parenteral, oral, transrectal, or transvaginal delivery systems described herein include a coating prepared to dissolve at a specific pH. In the case of two-phase delivery, the transrectal or transvaginal delivery system includes two coatings prepared to dissolve at different pH levels. In certain embodiments, the coatings are prepared to dissolve at a pH of approximately 5.5 to approximately 6.0 for targeting the duodenum; at a pH of approximately 7.3 to approximately 8.0 for targeting the ileum; or at a pH of approximately 5.5 to approximately 6.5 for targeting the colon. In certain embodiments, the coatings are prepared to dissolve at pH approximately 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. In certain embodiments, for two-phase delivery, one coating is prepared at pH approximately 7.3 to approximately 8.0 to target the ileum; and one coating is prepared at pH approximately 5.5 to approximately 6.5 to target the colon. In certain embodiments, for two-phase delivery, one coating is prepared at pH approximately 5.5 to approximately 6.0 to target the duodenum; and one coating is prepared at pH approximately 5.5 to approximately 6.5 to target the colon. In certain embodiments, for two-phase delivery, one capsule is prepared with a pH of approximately 5.5 to 6.0 to target the duodenum; and the other capsule is prepared with a pH of approximately 7.3 to 8.0 to target the ileum.
[0093] Also envisioned are enteric-coated formulations containing the disclosed exosomes or exosome preparations and lipophilic or hydrophilic materials; and pharmaceutically acceptable carriers or excipients thereof. Enteric-coated materials refer to polymers that are substantially insoluble in the acidic environment of the stomach and primarily soluble in intestinal fluid at a specific pH. The small intestine is part of the gastrointestinal tract (intestine) between the stomach and the large intestine and includes the duodenum, jejunum, and ileum. The pH of the duodenum is approximately 5.5, the pH of the jejunum is approximately 6.5, and the pH of the distal ileum is approximately 7.5. Therefore, enteric-coated materials will not dissolve at pH levels of approximately 5.0, 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 8.2, 8.4, 8.6, 8.8, 9.0, 9.2, 9.4, 9.6, 9.8, or up to approximately 10.0.Exemplary enteric materials that may be included in the transrectal or transvaginal delivery systems and compositions of mammalian exosomes described herein include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methyl methacrylate and methyl methacrylate, copolymer of methyl acrylate, methyl methacrylate and methacrylic acid, copolymer of methyl vinyl ether and maleic anhydride (Gantrez Examples include natural resins such as the ES series, ethyl methyl acrylate-methyl methacrylate-chlorotrimethylammonium ethyl acrylate copolymer, zein, shellac, copal colophonium, and several commercially available enteric-coated dispersion systems (e.g., Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D, Estacryl 30D, Coateric, and Aquateric). The solubility of each of the above substances is known or can be easily determined in vitro.
[0094] A two-phase capsule containing mammalian exosomes comprises first and second enteric coatings. In certain embodiments, the first enteric coating comprises a copolymer of methacrylic acid, methyl methacrylate, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, cellulose acetate trimellitate, sodium alginate, or zein. In certain embodiments, the second enteric coating comprises a copolymer of methacrylic acid, methyl methacrylate, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, cellulose acetate trimellitate, sodium alginate, or zein. In certain embodiments, the first enteric coating comprises a copolymer of methacrylic acid. In certain embodiments, the second enteric coating comprises a copolymer of methacrylic acid.
[0095] In certain embodiments, the enteric coating of the mammalian exosome composition described herein comprises a methyl methacrylate-methacrylate copolymer (1:1).
[0096] In certain embodiments, the gel, matrix, or excipient, together with the enteric coating, maintains the stability and potency of mammalian exosomes and / or a second plurality of mammalian exosomes at approximately 80–85% potency. In certain embodiments, the gel, matrix, or excipient maintains the potency of a first plurality of mammalian exosomes and / or a second plurality of mammalian exosomes at 24°C for at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 days at approximately 50%, 60%, 70%, or 80% potency. Potency or stability can be measured by any method suitable for determining the integrity of the exosome membrane structure or the potency and stability (e.g., not being degraded) of proteins or nucleic acids within the exosomes.
[0097] The transrectal or transvaginal delivery systems described herein include one or more coatings prepared to melt at normal body temperature or normal human body temperature. In the case of two-phase or single-phase delivery, the transrectal or transvaginal delivery system includes one or more coatings prepared to melt at different body temperatures. In certain embodiments, one or more coatings are prepared to melt at a temperature of about 36°C or higher. In certain embodiments, one or more coatings are prepared to melt at a temperature of about 36°C to about 47°C. In certain embodiments, one or more coatings are prepared to melt at a temperature of about 32°C to about 41°C. In certain embodiments, one or more coatings are prepared to melt at a temperature of about 34°C to about 45°C. In some embodiments, one or more coatings can be prepared to melt at temperatures of at least about 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, or 47°C. In some embodiments, one or more coatings can be prepared to melt at temperatures of up to approximately 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, or 47°C.
[0098] Also envisioned are exosome formulations comprising disclosed exosomes or exosome preparations and lipophilic or hydrophilic materials; and pharmaceutically acceptable carriers or excipients thereof. A lipophilic or hydrophilic coating material prepared to melt at normal body temperature refers to a material that is substantially insoluble at temperatures below normal body temperature and mainly soluble at temperatures above normal body temperature. Therefore, a lipophilic or hydrophilic coating material prepared to melt at normal body temperature will not melt up to, for example, a temperature of approximately 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, or 47°C.
[0099] The transrectal or transvaginal delivery systems of this specification include one or more coatings prepared to dissolve upon contact with an aqueous solution. In the case of two-phase delivery, the transrectal or transvaginal delivery system includes one or more coatings prepared to dissolve in different volumes of aqueous solution. In certain embodiments, one or more coatings are prepared to dissolve in an aqueous solution volume of about 5.6 mL or more. In certain embodiments, one or more coatings are prepared to dissolve in an aqueous solution volume of about 5.5 mL to about 20.5 mL. In certain embodiments, one or more coatings are prepared to dissolve in an aqueous solution volume of about 5.5 mL to about 13 mL. In certain embodiments, one or more coatings are prepared to dissolve in an aqueous solution volume of about 10.5 mL to about 20.5 mL. In some embodiments, one or more coatings can be prepared to dissolve in aqueous solutions of at least about 5.5 mL, 8 mL, 10.5 mL, 13 mL, 15.5 mL, 18 mL, or 20.5 mL. In some embodiments, one or more coatings can be prepared to dissolve in aqueous solution volumes of approximately 5.5 mL, 8 mL, 10.5 mL, 13 mL, 15.5 mL, 18 mL, or 20.5 mL.
[0100] Also envisioned are exosome formulations containing disclosed exosomes or exosome preparations and lipophilic or hydrophilic materials; and pharmaceutically acceptable carriers or excipients thereof. Lipophilic or hydrophilic coating materials prepared to dissolve in different aqueous solution volumes refer to materials that are substantially insoluble in volumes smaller than normal body fluid volumes and mainly soluble in volumes greater than normal body fluid volumes. Therefore, lipophilic or hydrophilic coating materials prepared to dissolve in different aqueous solution volumes are insoluble up to, for example, volumes of about 5.5 mL, about 8 mL, about 10.5 mL, about 13 mL, about 15.5 mL, about 18 mL, or about 20.5 mL.
[0101] Non-parenteral administration of transrectal or transvaginal delivery systems as described herein includes suppositories and enemas. Suppositories are generally formulated to be solid at room temperature and at least up to about 30°C, but to have a melting point lower than the normal human body temperature of about 37°C. Suppository formulations in this disclosure may have melting points of about 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, and 47°C or higher. Therefore, it is common to formulate suppositories using a fatty base such as cocoa butter that meets the above melting point criteria. Cocoa butter is a mixture of saturated and unsaturated fatty acid triglycerides that can be handled as a solid at room temperature but melts completely at body temperature. Other common fatty bases used in formulating suppositories include coconut oil, glycerin gelatin, hydrogenated oils, polyethylene glycol (PEG), or fatty acid esters of PEG. Other materials used in formulating suppositories include hard fats, macrogol, and various gelatin mixtures consisting of, for example, gelatin, water, and glycerol. Suitable commercially available lipid bases for suppository formulations include the above, in particular, semi-synthetic vegetable oil bases available in multiple grades such as Suppocire® AS, AS2X, and NA, including the lipophilic bases Suppocire® (Gattefosse); Novata® (Henkel Int.), e.g., Novata A, Novata B, and Novata BC; Witepsol® (Dynamit Nobel Ab), e.g., Witepsol® H5, H12, H15, H32, H35, W25, W31, W32, W32, W35, and W45; Massa Estarinum® (SASOL), e.g., Massa Estarinum® grades B, BC, E, and 299; Japocire®; and Ovucire®. The suppositories of the present invention may preferably contain any of the above-mentioned materials as a base. Hydrophilic waxes such as polyethylene glycol (e.g., PEG1500, PEG3000, PEG4000 and mixtures thereof) can also be used in the present invention.Suppocire AP is an amphiphilic base containing saturated polyglycolized glycerides. In some embodiments, the suppository form may contain further excipients such as binders and adhesives, lubricants, disintegrants, colorants and fillers, but are not limited to those described below. In some embodiments, the suppository contains any combination of the above base materials.
[0102] The non-parental administration of transrectal or transvaginal delivery systems described herein may optionally include a coating material that can alter the delivery of the therapeutic agent. The coating material can facilitate administration without interfering with the therapeutic activity of the product.
[0103] In some embodiments, suppositories containing one or more fatty acids are coated by any of the following methods: (i) coating the inner surface of the suppository mold with a coating material before molding the suppository; (ii) immersing the suppository in a liquid coating material; (iii) molding or casting the coating material around the suppository; or (iv) forming the coating by any other suitable method. The coating may include, but is not limited to, fats or oily bases, such as cocoa butter, hard fats and hydrogenated vegetable oils, waxes, water-soluble or water-miscible bases, such as polyethylene glycol, glycol-surfactant combinations and polyoxyethylene sorbitan fatty acid esters, and combinations thereof. Furthermore, the coated suppository may be in the form of a rectal capsule in which a core containing free fatty acids is covered with a water-soluble compound such as gelatin.
[0104] In some embodiments, the composition may further comprise cocoa butter, coconut oil, glycerin gelatin, hydrogenated oil, polyethylene glycol (PEG), or fatty acid esters of PEG.
[0105] In some embodiments, commercially available materials suitable for the coating according to the present invention include, but are not limited to, semi-synthetic vegetable oil bases available in multiple grades such as Suppocire® AS, AS2X, NA, the lipophilic bases Suppocire® (Gattefosse); Novata® (Henkel Int.), e.g., Novata A, Novata B, and Novata BC; Witepsol® (Dynamit Nobel Ab), e.g., Witepsol® H5, H12, H15, H32, H35, W25, W31, W32, W32, W35, and W45; Massa Estarinum® (SASOL), preferably Massa Estarinum® grades B, BC, E, and 299; Japocire®; and Ovucire®. The coating of the present invention may suitably contain any of the above-mentioned materials as a base. Hydrophilic waxes such as polyethylene glycol (e.g., PEG1500, PEG3000, PEG4000, and mixtures thereof) can also be used in the present invention. Suppocire AP is an amphiphilic base containing saturated polyglycolated glycerides. The above mixtures are also useful in the present invention. In some embodiments, a hard fat (e.g., a suitable Suppocire grade material) constitutes the main component of the coating material. Desired properties such as softening time and disintegration time can be adjusted by changing the relative amounts of components in the coating. Generally, increasing the amount of hydrophobic wax such as beeswax increases the softening time and disintegration time.
[0106] Furthermore, the coating material is preferably further enriched with a lubricant such as glyceryl dibehenate, although this is not limited to the coating material. In some embodiments, one or more pharmaceutically active ingredients may be added to the coating, and the one or more pharmaceutically active ingredients include, but are not limited to, local anesthetics and / or analgesics, such as lidocaine, prilocaine, benzocaine, chloroprocaine, bupivacaine, levobupivacaine, or other ester-type or amide-type local anesthetics, or any combination thereof.
[0107] In cases where particularly rapid local delivery is desired, other pharmaceutical compounds such as hydrocortisone may be included in the coating, although this is not limited to the following. Small suppositories for pediatric use are also within the scope of this invention. The coating material may be changed depending on the desired dose, the overall size of the suppository, or the release rate of the therapeutic composition.
[0108] The typical size of molded or kneaded suppositories for adults may be in the range of about 2–3 mL, for example, about 2.0 mL, about 2.2 mL, or about 2.5 mL. Depending on the composition of the excipients, this generally corresponds to the weight of the core excluding the coating in the range of about 1.5–3 g, and therefore, the suppositories according to the present invention are preferably within this weight range, for example, having a core of about 1.8 g, about 2.0 g, about 2.2 g, or about 2.5 g. The preferred size of suppositories for children will generally be about half of the above sizes, for example, in the range of 0.5–1.5 mL, for example, about 0.5 mL, about 0.8 mL, about 1.0 mL, about 1.2, or about 1.5 mL. The typical thickness of the coating layer covering the soft suppository core is about 0.1–3 mm.
[0109] The coating material may contain one or more fatty acids having chain lengths in the range of 4 to 36 carbon atoms, for example, chain lengths in the range of 4 to 24 carbon atoms, or chain lengths in the range of 8 to 24 carbon atoms. Preferably, the coating material contains a mixture of fatty acids, in which one or more fatty acids may be derived from suitable natural lipid materials such as animal or plant-derived oils, fractions thereof, or any combination thereof.
[0110] The coating materials include palmitoleic acid (16:1 n-7), cis-vaccenic acid (18:1 n-7), oleic acid (18:1 n-9), elaidic acid (18:1), linoleic acid (18:2 n-6), α-linolenic acid (18:3 n-3), γ-linolenic acid (18:3 n-6), moloctique acid (18:4 n-3), arachidonic acid (20:4 n-6), gadolic acid (20:1 n-11), gondic acid (20:1 n-9), cis-11 eicosenoic acid (20:11 n-7), eicosapentaenoic acid (20:5 n-3; EPA), erucic acid (22:1 n-9), cetoleic acid (22:1 n-11), and clupanodonic acid (22:5 The present invention may include unsaturated fatty acids such as n-3 and docosahexaenoic acid (22:6 n-3; DHA). Examples of vegetable oils used as raw materials for the fatty acids of the present invention include safflower oil, corn oil, almond oil, sesame oil, soybean oil, flaxseed oil, rapeseed oil, grapeseed oil, sunflower oil, wheat germ oil, hemp oil, or combinations thereof. In some embodiments, the fatty acids are derived from pharmaceutically acceptable oil materials (pharmaceutical-grade oils) as defined according to pharmacopoeia standards. Examples of such oils include marine omega oils such as Omega-3 Fish Oil (Lysi, Iceland).
[0111] In some embodiments, the suppository form of the present invention may contain an excipient oil component, such as triacylglyceride oil, to reduce discomfort during therapeutic administration related to bodily functions such as defecation. The excipient oil may be configured such that a desirable melting point is ensured for the entire composition of the dosage form.
[0112] Although the coating enables suppositories that do not contain preservatives, the coating may contain antioxidants, including, but not limited to, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), ascorbic acid or its salts, sulfatide salts, citric acid, propyl gallate, α-tocopherol, ascorbyl palmitate, or any combination thereof. In some embodiments, the coating may contain preservatives such as Ci₆-alkyl-p-hydroxybenzoic acid, for example, methyl-p-hydroxybenzoic acid, ethyl-p-hydroxybenzoic acid, propyl-p-hydroxybenzoic acid, butyl-p-hydroxybenzoic acid, or any combination thereof, which are any of the group consisting of benzoic acid or its derivatives.
[0113] In some embodiments, the coating may further contain a preservative, such as Ci₆-alkyl-p-hydroxybenzoic acid, for example, any of the group consisting of benzoic acid or its derivatives, such as methyl-p-hydroxybenzoic acid, ethyl-p-hydroxybenzoic acid, propyl-p-hydroxybenzoic acid, butyl-p-hydroxybenzoic acid, or any combination thereof.
[0114] In certain embodiments, the preservative is a mixture of methyl-p-hydroxybenzoic acid and propyl-p-hydroxybenzoic acid. The preservative may be present in the coating preparation at a concentration of about 0.05 to 0.2% by weight, or at other concentrations that do not impair the lipid activity.
[0115] The exosome formulations described herein are useful for the treatment of inflammatory disorders and autoimmune disorders in individuals. In certain embodiments, the inflammatory disorder or autoimmune disorder includes inflammatory disorders or autoimmune disorders of the gastrointestinal tract. In certain embodiments, the inflammatory disorder or autoimmune disorder of the gastrointestinal tract is inflammatory bowel disease. In certain embodiments, the inflammatory disorder or autoimmune disorder of the gastrointestinal tract is inflammatory Crohn's disease. In certain embodiments, the inflammatory disorder or autoimmune disorder of the gastrointestinal tract is colitis. In certain embodiments, the individual is a human individual. In certain embodiments, the individual is a cattle, horse, sheep, goat, pig, cat, or dog.
[0116] The exosome formulations described herein help reduce inflammation in an individual. In certain embodiments, the inflammation is inflammation of the gastrointestinal tract. The exosome formulations described herein help reduce the accumulation or activation of neutrophils in the gastrointestinal tract of an individual. In certain embodiments, the individual is a human individual. In certain embodiments, the individual is a cattle, horse, sheep, goat, pig, cat, or dog.
[0117] In certain embodiments, a therapeutic dose of the exosome composition contains approximately 1 billion to 2 trillion exosome particles.In a particular embodiment, the therapeutic dose of the exosome composition is approximately 100 billion to 250 billion exosome particles, approximately 100 billion to 500 billion exosome particles, approximately 100 billion to 750 billion exosome particles, approximately 100 billion to 1 billion exosome particles, approximately 100 billion to 1.25 trillion exosome particles, approximately 100 billion to 1.5 trillion exosome particles, and approximately 100 billion exosome particles. Exosome particles ~ approximately 2 trillion exosome particles, approximately 250 billion exosome particles ~ approximately 500 billion exosome particles, approximately 250 billion exosome particles ~ approximately 750 billion exosome particles, approximately 250 billion exosome particles ~ approximately 1 billion exosome particles, approximately 250 billion exosome particles ~ approximately 1.25 trillion exosome particles, approximately 250 billion exosome particles ~ approximately 1.5 trillion exosome particles, approximately 250 billion exosome particles ~ approximately 2 trillion exosome particles, approximately 500 billion exosome particles ~ approximately 750 Billions of exosome particles, approximately 500 billion exosome particles ~ approximately 1 billion exosome particles, approximately 500 billion exosome particles ~ approximately 1.25 trillion exosome particles, approximately 500 billion exosome particles ~ approximately 1.5 trillion exosome particles, approximately 500 billion exosome particles ~ approximately 2 trillion exosome particles, approximately 750 billion exosome particles ~ approximately 1 billion exosome particles, approximately 750 billion exosome particles ~ approximately 1.25 trillion exosome particles, approximately 750 billion exosome particles ~ approximately 1.5 trillion exosome particles It contains sosomal particles, approximately 750 billion to approximately 2 trillion exosome particles, approximately 1 billion to approximately 1.25 trillion exosome particles, approximately 1 billion to approximately 1.5 trillion exosome particles, approximately 1 billion to approximately 2 trillion exosome particles, approximately 1.25 trillion to approximately 1.5 trillion exosome particles, approximately 1.25 trillion to approximately 2 trillion exosome particles, or approximately 1.5 trillion to approximately 2 trillion exosome particles.In certain embodiments, a therapeutic dose of the exosome composition comprises approximately 100 billion exosome particles, approximately 250 billion exosome particles, approximately 500 billion exosome particles, approximately 750 billion exosome particles, approximately 1 billion exosome particles, approximately 1.25 trillion exosome particles, approximately 1.5 trillion exosome particles, or approximately 2 trillion exosome particles. In certain embodiments, a therapeutic dose of the exosome composition comprises at least approximately 100 billion exosome particles, approximately 250 billion exosome particles, approximately 500 billion exosome particles, approximately 750 billion exosome particles, approximately 1 billion exosome particles, approximately 1.25 trillion exosome particles, or approximately 1.5 trillion exosome particles. In certain embodiments, a therapeutic dose of the exosome composition may contain up to approximately 250 billion exosome particles, approximately 500 billion exosome particles, approximately 750 billion exosome particles, approximately 1 billion exosome particles, approximately 1.25 trillion exosome particles, approximately 1.5 trillion exosome particles, or approximately 2 trillion exosome particles. The dose may be formulated for oral, rectal, or vaginal administration.
[0118] Method for manufacturing a transrectal or transvaginal delivery system In certain embodiments, a method for preparing an oral delivery system is also described herein, which includes mixing a population of living cells with a matrix described herein and contacting the matrix:population of living cells composition with an enteric coating. In certain embodiments, the matrix:population of living cells composition is added to a capsule and then an enteric coating is applied. In certain embodiments, a method for preparing an oral delivery system is also described herein, which includes mixing a population of living cells with a matrix containing agar described herein and contacting the matrix:population of living cells composition with an enteric coating containing a copolymer of methacrylic acid.
[0119] In another embodiment, a method for preparing a composition of mammalian exosomes formulated for oral delivery includes mixing a plurality of mammalian exosomes with a matrix containing about 1.0% to about 2.0% methylcellulose and about 1.0% to about 2.0% alginate gel to provide a cell matrix, and applying an enteric coating to the cell matrix. In certain embodiments, the matrix contains about 1.3% to about 1.8% methylcellulose and about 1.3% to about 1.8% alginate gel. In certain embodiments, the matrix contains about 1.5% methylcellulose and about 1.5% alginate gel. In certain embodiments, methylcellulose and alginate gel are present in a ratio of about 1:1. In certain embodiments, the enteric coating contains a methyl methacrylate-methacrylate copolymer (1:1). In certain embodiments, the plurality of mammalian exosomes include human exosomes. In certain embodiments, the plurality of mammalian exosomes include non-human exosomes.
[0120] In certain embodiments, a method for preparing a transrectal or transvaginal delivery system is also described herein, which includes mixing the matrix with the matrix described herein and contacting the matrix:exosome preparation with a lipophilic or hydrophilic coating. In certain embodiments, the matrix:exosome preparation is added to a capsule and then coated with a lipophilic or hydrophilic coating. In certain embodiments, a method for preparing a transrectal or transvaginal delivery system is also described herein, which includes mixing the exosome preparation with the agar-containing matrix described herein and contacting the matrix:exosome preparation with an excipient or a lipophilic or hydrophilic coating containing a copolymer of methacrylic acid.
[0121] In certain embodiments, methods for preparing transrectal or transvaginal delivery systems are also described herein, which include mixing an exosome preparation with a matrix containing agar as described herein, and contacting the matrix:exosome preparation with an excipient or a lipophilic or hydrophilic coating containing cocoa butter, coconut oil, glycerin gelatin, hydrogenated oil, polyethylene glycol (PEG), or fatty acid esters of PEG.
[0122] In certain embodiments, a method for preparing an oral delivery system is also described herein, which includes mixing an exosome preparation with a matrix described herein and contacting the matrix:exosome preparation with an enteric coating. In certain embodiments, the matrix:exosome preparation is added to a capsule and then coated with an enteric coating. In certain embodiments, a method for preparing a transrectal delivery system is also described herein, which includes mixing an exosome preparation with a matrix containing agar described herein and contacting the matrix:exosome preparation with an enteric coating containing an excipient or a copolymer of methacrylic acid.
[0123] In another embodiment, a method for preparing an exosome preparation formulated for transrectal or transvaginal delivery includes mixing the exosome preparation with a matrix containing about 0.5% to about 3.0% methylcellulose and about 0.5% to about 3.0% alginate gel to provide a cell matrix, and applying a lipophilic or hydrophilic coating to the cell matrix. In certain embodiments, the matrix contains about 1.0% to about 2.0% methylcellulose and about 1.0% to about 2.0% alginate gel. In certain embodiments, the matrix contains about 1.3% to about 1.8% methylcellulose and about 1.3% to about 1.8% alginate gel. In certain embodiments, the matrix contains about 1.5% methylcellulose and about 1.5% alginate gel. In certain embodiments, the methylcellulose and alginate gel are present in a ratio of about 1:1. In certain embodiments, the lipophilic or hydrophilic coating comprises a methyl methacrylate-methacrylic acid copolymer (1:1). Specific Embodiments 1. A composition for non-parenteral and / or transrectal or transvaginal delivery of mammalian exosomes, the composition comprising a lipophilic or hydrophilic coating surrounding a plurality of mammalian exosomes mixed with a solid matrix, the matrix comprising a matrix comprising about 0.5% to about 3.0% methylcellulose and about 0.5% to about 3.0% alginate gel. 2. The composition according to Embodiment 1, wherein the matrix comprises a matrix containing about 1.0% to about 2.0% methylcellulose and about 1.0% to about 2.0% alginate gel. 3. The composition according to Embodiment 1, wherein the matrix comprises about 1.3% to about 1.8% methylcellulose and about 1.3% to about 1.8% alginate gel. 4. The composition according to Embodiment 1, wherein the matrix comprises about 1.5% methylcellulose and about 1.5% alginate gel. 5. The composition according to any one of Embodiments 1 to 4, wherein the matrix comprises a ratio of approximately 1:1 methylcellulose to alginate gel. 6. The composition according to any one of Embodiments 1 to 5, wherein the exosome is a mesenchymal stem cell exosome or a hematopoietic stem cell exosome. 7. The composition according to Embodiment 6, wherein the exosome is a hematopoietic stem cell exosome. 8. The composition according to Embodiment 6, wherein the exosome is a mesenchymal stem cell exosome. 9. The composition according to Embodiment 8, wherein the mesenchymal stem cells are type I mesenchymal stem cells. 10. The composition according to Embodiment 8, wherein the mesenchymal stem cells are type II mesenchymal stem cells. 11. The composition according to any one of Embodiments 8 to 10, wherein the exosome comprises a protein or nucleic acid selected from the list consisting of CD81, CD63, CD9, HSP60, HSP70, HSP90, VEGF, PGE2, and combinations thereof. 12. The composition according to any one of Embodiments 8 to 10, wherein the exosome comprises a nucleic acid selected from the list consisting of miRNA Let7, 155, 146, 122, and combinations thereof. 13. The composition according to any one of Embodiments 1 to 12, wherein the mammalian exosome has a diameter of about 30 nanometers to about 150 nanometers. 14. The composition according to any one of Embodiments 1 to 13, wherein the mammalian exosome is a human exosome. 15. The composition according to any one of Embodiments 1 to 13, wherein the mammalian exosomes are exosomes of a dog, cat, cow, horse, sheep, or pig. 16. The composition according to any one of Embodiments 1 to 15, which is formulated for transrectal delivery. 17. The composition according to any one of Embodiments 1 to 15, which is formulated for transvaginal delivery. 18. The formulation is a composition according to any one of Embodiments 1 to 16, wherein the formulation does not swell upon contact with an aqueous medium. 19. The lipophilic or hydrophilic coating is melted at normal body temperature or at 36°C or higher, according to any one of Embodiments 1 to 18. 20. The composition according to any one of Embodiments 1 to 19, wherein the lipophilic or hydrophilic coating essentially consists of cocoa butter, coconut oil, glycerin gelatin, hydrogenated oil, polyethylene glycol (PEG), fatty acid esters of PEG, or a lipophilic base from Gattefosse. 21. The lipophilic or hydrophilic coating is a composition according to any one of Embodiments 1 to 19, comprising cocoa butter, coconut oil, glycerin gelatin, hydrogenated oil, polyethylene glycol (PEG), fatty acid ester of PEG, or a lipophilic base from Gattefosse. [Examples]
[0124] The following exemplary examples are representative of the embodiments of the compositions and methods described herein and are not intended to limit them in any way.
[0125] Example 1 - Collection of mammalian exosomes from mesenchymal stem cells Collection of MSC exosomes MSCs are incubated at 37°C in a humidified atmosphere containing 5% CO2. The adherent cells are grown until they reach approximately 80% confluence. The morphology of isolated and grown MSC cells is evaluated during the cell culture period using light microscopy and FACS analysis.
[0126] To generate and collect exosomes, cells are cultured in an optimal growth medium for up to 72 hours (<2% exosome-free). Following the culture and subsequent priming period, the cell supernatant is collected, and exosomes are isolated using the Fab-TACS® Exosome Isolation Kit (IBA Lifesciences, ThermoFisher Scientific, CA).
[0127] Concentrate CD9 and CD81-positive exosomes from MSC cell culture supernatant using the corresponding Fab-TACS® Exosome Isolation Kit according to the included manual. Briefly, centrifuge the MSC cell culture supernatant at 3000×g for 10 minutes. Filter the supernatant through a 0.2 μm polyethersulfone filter. Filter the elution buffer and PBS through a cellulose acetate filter (0.2 μm). After draining the storage buffer, load Fab-Streps onto the column. Transfer 1 ml of filtered culture medium to the column. After washing, apply filtered biotin elution buffer to the matrix to collect exosomes. Analyze the exosome size using a NanoSight LM10 instrument (Malvern Instruments), and process the data using Nanoparticle Tracking Analysis [NTA] software 2.3. Protein content is determined by standard protein assays or Western blotting using monoclonal detection antibodies for CD9, Alix, and CD63.
[0128] Example 2 - Stability of exosomes under different pH and gastrointestinal conditions Exosomes [5 billion particles] from human adult tissue-derived mesenchymal stem cells were added to an oral formulation (coated with an enteric coating of 0.67% w / v alginate and 0.67% w / v methylcellulose, methyl methacrylate-methacrylate copolymer (1:1)). The enteric-coated capsules were then treated to simulate the pH changes expected as the capsules move from the oral cavity to the ileum and colon. Specifically, they were incubated at pH=1.2 for 2 hours, then at pH 4.2 for 30 minutes, at pH 6.8 for 30 minutes, and finally at pH=7.4 for over 2 hours. The exosomes were then harvested, concentrated 10-fold, and measured. Figures 6A and 6B show that the enteric-coated capsules did not release their payload until the pH became neutral above 6.8. Figure 6B shows the number of recovered and stained particles for exosome-specific markers CD63, CD81, and CD9 from each sample measured with NanoSight NS300 and analyzed with ExoViewAnalyzer3.0 [R100, NanoView Biosciences, MA]. Figure 6C shows that the recovered exosomes were intact, as demonstrated by immunofluorescence microscopy.
[0129] Enteric-coated capsules containing exosomes [5 billion particles] were treated to mimic the pH changes expected as the capsules migrate from the oral cavity to the ileum and colon. Therefore, after incubation at pH=1 (USP standard, simulated gastric fluid, SIG) for 2 hours, neutralization was performed at pH=7.5 in simulated intestinal fluid (USP, SIF) for 2 hours, cells were collected, and assays were performed as described above. Figures 7A and 7B show that the enteric-coated capsules did not release their payload until neutral SIF was reached. This figure shows the number of particles collected and stained for exosome-specific markers CD63 (red), CD81 (blue), and CD9 (green) from each sample (IgG isotype negative control, gray) measured with NanoSight NS300 and analyzed with ExoViewAnalyzer3.0 [R100, NanoView Biosciences, MA]. Figure 7C shows that the recovered exosomes are intact, as demonstrated by immunofluorescence microscopy.
[0130] The recovery rates of such exosomes after incubation at high pH (mimicking the stomach and upper gastrointestinal tract), and after incubation in simulated gastric juice, at a pH that replicates the lower gastrointestinal tract, are remarkable. This is because the exosome composition containing an alginate and methylcellulose matrix has alginate gel pores measuring 5-150 nm [25-200 kDa], while the exosomes themselves are approximately 70-150 nM. Nevertheless, the matrix is thought to retain the exosomes in a pH-dependent manner, allowing them to pass through the low pH / high proteolytic environment of the upper gastrointestinal tract intact and be delivered to the colon.
[0131] Example 3 - Treatment of an IBD mouse model with an oral exosome preparation The efficacy of the oral exosome formulations described was tested in a dextran sulfate sodium (DSS)-induced colitis model. This model is an established and validated model of inflammatory bowel disease (IBD) and closely resembles human IBD. See Li et al. "Mesenchymal stem cells and acellular products attenuate murine-induced colitis," Stem Cell Research and Therapy (2020) 11:515. In these experiments, colitis was induced in mice by administering DSS at a concentration of 3% w / v in drinking water. Briefly, DSS (MW approximately 40,000, Sigma-Aldrich, St. Louis, MO) was administered daily in drinking water throughout the study period. As shown in Figure 8A, for each study, mice (n=6 per group) were randomly assigned to one of the following groups: (a) untreated wild-type control group, (b) DSS treatment only group, (c) DSS oral (PO) exosome [10 billion particles] group, (d) DSS PO MSC [1 million cells] group, and (e) DSS and oral formulation vehicle control group. Mouse body weight, clinical signs, stool consistency, and color were observed daily. Vehicle, exosomes, and MSCs were administered orally as indicated on days 1, 3, and 5 of the study (DSS administration started on day 0). Clinical scoring was performed using the modified scoring matrix shown in Figure 8A. Fecal occult blood was measured using a test kit (Fisher Healthcare, Houston, TX). As shown in Figure 8B, this treatment with orally formulated exosomes resulted in a significant reduction in symptoms associated with DSS-induced colitis in mice.
[0132] Example 4 - Retention of broad anti-inflammatory properties of oral exosome formulations Preclinical studies in affected animals have demonstrated that the primary therapeutic benefit of exosome therapy lies in neutrophil infiltration and attenuation of inflammatory factors released by neutrophils. Efficacy assays were devised to measure specific inflammatory factors released by activated neutrophils. Neutrophils were obtained from the bankable and standardizable established ATCC human neutrophil-like cell line [HL60]. These cells were co-cultured alone (negative control), with anti-inflammatory MSCs, or with exosomes (positive control cells, starting exosome products), i.e., oral exosome products recovered from pH studies and 10-fold concentrated. The effects on the expression of specific inflammatory factors were evaluated by RT-qPCR assays.
[0133] In short, HL60 cells were cultured in RPMI, followed by the addition of 1.3% DMSO for 3 days to induce neutrophil-like cell formation. Next, 2.5 million neutrophil-like HL60 cells / mL were transferred to 24-well plates containing adherent human BM MSCs [250,000 cells -0.1x, positive control] or 5 billion EVs, and activated overnight with 10 μg / mL LPS or left unactivated [negative control]. Subsequently, HL60 cells were harvested, RNA was extracted using the miRNAeasy kit [Qiagen, MD], and real-time qPCR was performed using BioRad CFX96 [BioRad, CA] with human gapdh as the normalized housekeeping gene.
[0134] Exemplary data from such assays are shown in Figure 9, demonstrating that the key mechanism of action of the exosomes described is the inhibition of neutrophil activity, and consequently, the inhibition of inflammation in general.
[0135] While preferred embodiments of the present invention have been illustrated and described herein, it will be apparent to those skilled in the art that such embodiments are provided merely as examples. Those skilled in the art will conceive of numerous variations, modifications, and substitutions without departing from the present invention. It should be understood that various alternative forms to the embodiments of the present invention described herein may be used in carrying out the present invention.
[0136] All publications, patent applications, issued patents, and other documents referenced herein are incorporated by reference in the same way that the entirety of each individual publication, patent application, issued patent, or other document is specifically and individually indicated. Any definitions contained in the incorporated text are excluded where they conflict with the definitions in this disclosure.
Claims
1. 1. A composition for oral delivery of mammalian exosomes, the composition comprising a plurality of mammalian exosomes mixed with a matrix and surrounded by an enteric coating, the matrix comprising about 0.1% to about 5.0% methylcellulose and about 0.1% to about 5.0% alginate.
2. The composition of claim 1 , wherein the matrix comprises about 0.5% to about 1.0% methylcellulose and about 0.5% to about 1.0% alginic acid.
3. The composition of claim 1 , wherein the matrix comprises about 0.25% to about 0.75% methylcellulose and about 0.25% to about 0.75% alginic acid.
4. A composition described in any one of claims 1 to 3, wherein the matrix comprises a ratio of methylcellulose to alginic acid of approximately 1:
1.
5. The composition described in any one of claims 1 to 3, wherein the mammalian exosomes are mesenchymal stem cell exosomes or hematopoietic stem cell exosomes.
6. The composition described in claim 5, wherein the mammalian exosomes are hematopoietic stem cell exosomes.
7. The composition described in claim 5, wherein the mammalian exosomes are mesenchymal stem cell exosomes.
8. The composition described in any one of claims 1 to 3, wherein the mammalian exosomes have a diameter of about 30 nanometers to about 150 nanometers.
9. The composition described in any one of claims 1 to 3, wherein the mammalian exosomes are human exosomes.
10. The composition described in any one of claims 1 to 3, wherein the mammalian exosomes are canine, feline, bovine, equine, ovine, or porcine exosomes.
11. A composition described in any one of claims 1 to 3, wherein the enteric coating comprises methyl methacrylate-methacrylic acid copolymer (1:1).
12. The composition described in any one of claims 1 to 3, wherein the composition contains at least 100 billion exosomes.
13. A composition described in any one of claims 1 to 3, wherein after 2 hours of incubation at pH 1.2, 40% or more of intact exosomes are recovered from the composition compared to the initial amount.
14. A pharmaceutical composition for use in treating neutrophil accumulation or neutrophil activation in the gastrointestinal tract of an individual, comprising a composition according to any one of claims 1 to 3, wherein the pharmaceutical composition is adapted for oral administration.
15. A pharmaceutical composition for use in treating an inflammatory or autoimmune disorder in an individual, comprising the composition of any one of claims 1 to 3, wherein the pharmaceutical composition is adapted for oral administration.
16. The pharmaceutical composition described in claim 14 or 15, wherein the individual is a human individual.
17. The pharmaceutical composition described in claim 14 or 15, wherein the individual is a dog, cow, cat, pig, horse, or sheep.
18. The pharmaceutical composition of claim 15, wherein the inflammatory or autoimmune disorder is a gastrointestinal inflammatory or autoimmune disorder.
19. The pharmaceutical composition of claim 18, wherein the gastrointestinal inflammatory or autoimmune disorder comprises inflammatory bowel disease or Crohn's disease.
20. The pharmaceutical composition of claim 18, wherein the gastrointestinal inflammatory or autoimmune disorder comprises inflammatory bowel disease (IBD).
